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Abstract
Cancer is a leading cause of disease and death around the world, and is thought to be the
largest challenge to human beings in the 21st century due to the lack of efficient treatments. A
promising strategy for discovering anti-cancer drug candidates is to develop novel
sialyltransferase transition-state analogue inhibitors as potential anti-metastasis drugs, to
control cancer cell metastasis, and to prevent primary tumours turning into deadly secondary
tumours. This thesis describes work towards the synthesis of sialyltransferase transition-state
analogue inhibitors 15a-i, and in particular, three key fragments: α-hydroxyphosphonate
derivatives, the protected cytidine component and the key phosphoryl linkage.
The α-hydroxyphosphonate derivatives were prepared as both key components of the
sialyltransferase transition-state analogue inhibitors and also as bioactive molecules
themselves. Nine diethyl α-hydroxyphosphonate derivatives 16a-i, nine dibenzyl αhydroxyphosphonate derivatives 17a-i and one hydroxyphosphonic acid (29), were prepared
in an efficient, inexpensive and readily accessible manner. Six of the compounds were novel,
while another two were novel at the commencement of the project, but were described in the
literature during the course of the project. Biological evaluation of the α-hydroxyphosphonate
derivatives showed that selected examples exhibited promising protein kinase A inhibitory
activity of 85-100% when tested at 100 µg/ml.
A large scale (overall more than 10 g) of the tri-N/O-acetylated cytidine (18) was
obtained as the key precursor for the phosphoramidite coupling step in a highest overall yield
of 64%. The two intermediate products, the silyl protected cytidine (31) and silyl protected
tri-N/O-acetylated cytidine (32), were fully characterised and their reaction conditions
optimised to give excellent yields of product (>90%). Moreover, the successful synthesis of
the 2’, 3’-O-isopropylidene-cytidine (33) in 78% yield provided a simplified, one-step
method for preparation of an alternative protected cytidine for coupling to the αhydroxyphosphonates.
Two different approaches (the phosphoramidite approach and the phosphotriester
approach) were investigated to introduce the key phosphoryl linkage that links the αhydroxyphosphonate derivatives 16a-i and 17a-i with the protected cytidine component (18).
In the phosphoramidite approach for preparing the sialyltransferase transition-state analogue
inhibitors, 5-ethyl-thio-1-H-tetrazole (SET) was explored as an activator, as the most
commonly used activator 1H-tetrazole is unavailable in Australia. The key 5’-amidite (21)
xviii

intermediate was successfully prepared under modified conditions, accompanied with a byproduct (48) that was characterised and its formation explained. In addition, a phosphotriester
approach was investigated as a new and potentially more efficient way to generate the desired
sialyltransferase transition-state analogue inhibitors.
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Introduction
1.1 General introduction
Cancer is a noncommunicable chronic disease that can affect almost any part of
the human body with cancer cells growing and spreading uncontrolledly. It is a
leading cause of disease and death around the world, resulting in approximately 12.7
million cancer cases and 7.6 million deaths (around 13% of all deaths) in 2008.[1]
Among these, approximately 47% cases of cancer and 55% of cancer-related deaths
occurred in less developed regions of the world, in which effective resources for
treatment are relatively lacking. There are many different causes of cancer, of which
some are well understood, while some others are not. Some common risk factors
include an unhealthy lifestyle (such as smoking, excessive alcohol consumption, lack
of physical exercise and poor diet), exposure to occupational or environmental
carcinogens (e.g. asbestos, in-door air pollution) and some infections are deemed as
major causes of cancer. With the effect of global population growth and aging, the
number of cancer cases will inevitably increase.[2] According to the World Cancer
Factsheet generated by the World Health Organisation, International Agency for
Research on Cancer, it is expected that new cancer cases will increase to a staggering
22.2 million, and cancer-related deaths to 13.2 million, by 2030.[1] Therefore, cancer
is thought to be the largest challenge to human beings in the 21st century.

1.2 Molecular biology of cancer
In general, cancer cells are formed from normal cells, with defects in their normal
regulatory mechanism, resulting in uncontrolled growth and multiplication. The
1
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expression of oncogenes and the inactivation of cancer suppression genes lead to the
defect. Furthermore, there are several key features found in cancer cells, which
include defective signalling pathways, a number of overproduced crucial proteins
such as growth factors, receptors and kinases, stimulating cell growth and division.
The progression through the cell cycle phase (known as G1, S, G2, M) is thought to be
regulated by overactive cylins and cyclin dependent kinases (CDKs). Moreover,
defective apoptosis leads to regulatory proteins that cannot detect and moderate
abnormal or faulty cells. With the growth of cancer cells, a stable supply of basic
nutrients such as amino acids, nucleic acids and carbohydrates is required.
Angiogenesis, the process where new blood vessels are formed and provide nutrients
to cells, facilitates cancer cell growth.[3]
It is known that not all cancers are deadly, but rather metastases are the major
cause of death from cancer. Primary tumours are often localized at a particular part of
the body and can grow to a size as big as a football. However, they are not always
threatening to a human being’s life. It is metastasis, the process whereby primary
tumour cells break away from the origin, invade a blood vessel and travel though the
circulation and set up a secondary tumour in other organs of the body, that most often
form the fatal malignant cancer.[4] In 2011, Rambaruth et al. reviewed the main steps
of cancer cell metastasis involving primary tumour mass infiltration, intravasation,
angiogenesis, extravasation and development of secondary tumour masses (see
Figure 1.1). They also pointed out that most of these steps are mediated by glycans
on the cell surface and their interactions with carbohydrate-binding lectins.[5]
The molecular biology of cancer is complicated, and these different processes and
their mechanism of action involve numbers of bioactive molecules such as proteins
(enzymes, growth factors, receptors), nucleic acids and glycoconjugates, which
provide various potential treatment targets for developing anti-cancer agents.

2
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Figure 1.1 Main steps of cancer cell metastasis.[5]

1.3 Treatment of cancer
Surgery, radiotherapy and chemotherapy are the three current treatments for
cancer. Among these, chemotherapy usually comprises a combination of different
drugs, which are developed according to different mechanisms. Most traditional anticancer drugs exhibit their cytotoxicity by disrupting functional DNA (see Figure 1.2).
The intercalating agent doxorubicin (1) is one of the most effective anti-cancer drugs
that has been developed to-date. This kind of agent can insert their planar moiety into
the major groove of DNA and interact with nucleic acid base pairs via Van der Waals
interactions. Moreover, the charged amino group of doxorubicin (1) also plays a
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crucial role in reacting with negatively charged phosphate groups in DNA. Alkylating
agents such as nitrogen mustards are other important anti-cancer agents. Chlormethine
(2) is the first nitrogen mustard to be used in the clinic. It works by inhibiting
replication of DNA, which is achieved by forming a highly electrophilic aziridinium
ion, resulting in cross-linking of two DNA chains or within one chain. The metallating
agent cisplatin (3) is a widely used anti-cancer drug. When it enters the aqueous
environment, it loses the chloro substituents and forms a highly reactive metallating
agent, that consequently cross-links DNA and inhibits transcription.
Different to the direct action on DNA of the drugs described above, the
thymidylate synthase inhibitor 5-fluorouracil (4) disrupts the function of DNA by
inhibition of an enzyme involved in DNA synthesis. The hydrogen on the 5-position
of uracil is important for the biosynthesis of thymidylate. 5-Fluorouracil (4) mimics
the natural substrate uracil, and irreversibly binds to the active site of thymidylate
synthase, terminating the biosynthesis and disrupting the synthesis of DNA.[6]
Due to the fact that drugs which target functional DNA can’t distinguish between
cancer cells and normal cells, many of these drugs have severe side-effects. Thus, new
anticancer agents that work on other different molecular targets are currently being
developed for decreasing the toxic side effects. For example, cyclin dependent kinases
(CDKs) are important enzymes which mediate the key protein cyclins in the cell
cycle. CDKs are usually found to be over-expressed in many cancer cells, which
suggest they are a potential target for cancer treatment. A promising bioactive
compound flavopiridol (5) that targets CDKs is currently in clinical trials. [7]
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Figure 1.2 Chemotherapeutic drugs.

1.4 Promising

anti-metastasis

target

for

cancer

treatment:

sialyltransferases
1.4.1 Sialic acid
1.4.1.1 Structure and function
Sialic acid is the second most important sugar in nature, next to glucose. Sialic
acids are a large family of neuraminic acid derivatives with more than 50 analogues
described to date. They all share a nine-carbon backbone bearing a carboxyl group at
the 1-position, a hydroxyl group at the 2-position and an amino group at the 5position. N-Acetylneuraminic acid (Neu5Ac) (6) and 5-glycolylneuraminic acid
(Neu5Gc) (7) are the two most well-known members of this family (see Figure
1.3).[8-11]
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Figure 1.3 Structures of sialic acids, Neu5Ac (6) and Neu5Gc (7).

Sialic acids are typically found in cellular secretions and on the outer surface of
cells, at the terminal position of N- and O- linked oligosaccharides attached to protein
or lipid moieties at the cell surface.[12] The diverse structures of sialic acids and their
sialylated glycoconjugates allow them to participate in molecular recognition, which
are performed by specific interaction with sugar recognizing and binding lectins (see
Figure 1.4).[13] These special features suggest that sialic acids play essential roles in
a variety of biological progresses, such as cell-cell interaction, adhesion, protein
targeting, viral and bacterial infection, and tumour metastasis.[9, 14, 15]

Figure 1.4 Recognition events sialic acid participates in.[13]
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1.4.1.2 Sialic acid metabolism
Due to the great importance of sialic acid in biological processes, the metabolic
pathway of sialic acid biosynthesis is attracting increasing attention. Even though the
metabolic pathways of sialic acid in eukaryotes and bacteria are different, they both
involve a similar process of biosynthesis, activation, transfer and recycling.[16]
Cytosolic glucose is converted to N-acetylmannosamine (ManNAc) in the presence of
several enzymes, followed by phosphorylation of ManNAc to Man-NAc-6-phosphate
(MaNAc-6-P). MaNAc-6-P is further converted into Neu5Ac, which is consequently
activated

to

the

sialic

acid

transfer

donor,

cytidine

monophosphate-N-

acetylneuraminic acid (CMP-Neu5Ac), in the nucleus. Then, the newly formed CMPNeu5Ac works as a substrate to transfer the sialic acid residue to oligosaccharides,
generating sialyl-oligosaccharides. This process is mediated by enzymes called
sialyltransferases (see Figure 1.5).[17]

Figure 1.5 Metabolism of sialic acid.[17]
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1.4.2 Sialyltransferase
1.4.2.1 Proposed mechanism of sialyl transfer
Sialyltransferases have been found in eukaryotes, viruses and bacteria, and
mediate the sialic acid residue transferring from CMP-Neu5Ac to acceptor sugars. In
1996, Horenstein et al. firstly reported a proposed SN1-like sialyl transfer mechanism.
The key features of this mechanism are that the sialyl donor CMP-Neu5Ac is
activated involving formation of a planar oxocarbenium ion. Consequently, the
hydroxyl group in the sialyl acceptor sugar undergoes nucleophilic attack at the
anomeric carbon, to dissociate the CMP moiety and transfer the sialic acid to the
glycoconjugate (see Figure 1.6).[18] This proposed mechanism provides a basis for
sialyltransferase inhibitor design and development. Sialyltransferase inhibitors that
mimic the proposed transition-state (CMP-Neu5Ac≠), have shown a much greater
affinity towards sialyltransferases than other inhibitors developed to-date.[19-22]
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Figure 1.6 Proposed mechanism of sialyl transfer.[18]
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1.4.2.2 Sialyltransferase classification
Sialyltransferases are a large family of enzymes. According to their different
linkage patterns and specificity of acceptors, the whole family of sialyltransferases are
classified into four types: the β-galactoside α-2,3-sialyltransferases (ST3Gal I-VI), the
β-galactoside

α-2,6-sialyltransferases

(ST6Gal

I,

II),

the

GalNAc

α-2,6-

sialyltransferases (ST6GalNAc I-VI), and the α-2,8-sialyltransferases (ST8Sia I-VI)
(see Figure 1.7).[23, 24] As shown in Figure 1.6, α-2,6-sialyltransferases catalyse the
sialic C2 residue linking with the hydroxyl group at C6 of the sialyl acceptor sugars.
Based on the acceptor sugar, the α-2,6-sialyltransferases can be further divided into
more subtypes. Furthermore, based on the sequence similarities in the CAZy
(carbohydrate-active enzymes) database, sialyltransferases can also be classified into
five families, which are the GT29, GT38, GT42, GT52, and the GT80 families. Most
mammalian

sialyltransferases

fall

into

the

GT29

family,

while

bacterial

sialyltransferases fall into the GT38, GT42, GT52, and GT80 families, although there
are no overall sequence similarities between these two kinds of sialyltransferases.[11]

Figure 1.7 Classification of sialyltransferases based on different linkage patterns.[24]
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1.4.2.3 Sialyltransferase X-ray crystal structure
The X-ray crystal structures of five types of sialyltransferases of bacterial origin
have been reported.[25-28] In 2004, Chiu et al. reported the first crystal structure of a
sialyltransferase (Cst-II), which was isolated from Campylobacter jejuni, in complex
with CMP-3F-Neu5Ac as a substrate analogue. The structural and kinetic data
supported the previously proposed mechanism and binding mode shown in Figure
1.6, where a histidine acts as a general base and the sialic acid donor is displaced
through a planar oxocarbenium ion transition state, and two tyrosine residues can
coordinate to the phosphate group and help to release the CMP.[25] In 2008, Kim et
al. reported the crystallization of an α-2,6-sialyltransferase (PM01088) from
Pasteurella multosida, and pointed out the residues Asp 141, His 311, Glu 338, Ser
355 and Ser 356 are important for binding, in which, Asp 141 is crucial due to its role
as a base.[26] However, these bacterial sialyltransferases possess very low sequence
homology (typically 10- 15% identity) to mammalian sialyltransferases.[29]
Based on the sequence similarities in the CAZy (carbohydrate-active enzymes)
database, most mammalian sialyltransferases belong to the GT29 family, and
obtaining a suitable level of stable and soluble protein is the biggest challenge for
characterisation of this protein family. This problem was overcome by Rao et al. in
2009, who reported the first crystal structure of a mammalian sialyltransferase
(porcine ST3Gal-I), which has 85% homology with the analogous human
sialyltransferase.[29] In Figure 1.8, the product CMP and the sialyl acceptor
disaccharide sugar are shown as yellow sticks, and the important catalytic base (His
319) is highlighted in blue. All the structural and kinetic data in this paper provides a
mechanistic insight into mammalian sialyltransferases, and offers a structural basis for
both understanding of the sialic acid transferring mechanism and for the design and
development of new sialyltransferase inhibitors.
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Figure 1.8 Porcine ST3Gal-I crystal structure.[29]

1.4.3 Sialyltransferases as a new target for cancer treatment
Sialyl Lewisa (SLea; NeuAcα2,3Galβ1,3[Fucα1,4]GlcNAc) and its isomer sialyl
Lewisx

(SLex;

NeuAcα2,3Galβ1,4[Fucα1,3]GlcNAc)

are

well

known

as

tetrasaccharide carbohydrate ligands for carbohydrate binding selectins, and are
regarded as key tumour-associated antigens.[30] Both SLea and SLex are found in
elevated levels in metastatic cells, whereby they facilitate adhesion to the
endothelium, initiating the process of extravasation and metastasis.[31, 32] In 2005,
Peracaula et al. pointed out that the formation of sialyl Lewis antigens, which are
involved in expression of sialylated epitopes, is correlated to sialyltransferase activity
levels.[33] Moreover, variation in the amount of sialic acid, in other words, altered
sialylation and altered sialyltransferase expression is widely reported to positively
correlate with cancer metastasis and poor prognosis.[34-36] In 2003, Drinnan and
colleagues reviewed the reported relationship between sialyltransferase expression
and different cancer diseases. In colon and breast cancer, α-2,6-sialyltransferase was
observed to be over expressed. While α-2,3-sialyltransferase over expression was
observed in breast, pancreatic cancer and leukemia.[37] Therefore, different from
11
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traditional anti-cancer drugs, which mostly focus on cancer cell growth inhibition or
directly killing cancer cells, inhibition of sialyltransferases provides a promising new
strategy to control cancer cell metastasis, to prevent primary tumours turning to
deadly secondary tumours.

1.5 Sialyltransferase inhibitors
1.5.1 Reported sialyltransferase inhibitors
During the past 20 years, a number of bioactive compounds with structures
varying from mimics of the natural donor CMP-sialic acid, to steroid related
lithocholic acid derivatives isolated and modified from Nature, were designed and
prepared to inhibit sialyltransferases. Initially, sialyltransferase inhibitors were
designed based on the natural donor and acceptor to competitively inhibit the
enzymes. Various donor analogues [19, 21], acceptor analogues [38], bi-substrate
analogues [39] and transition-state analogues [20] have been prepared and shown to
display a wide range of affinities for sialyltransferases. In addition, a few derivatives
isolated from Nature also show great inhibition activities (see Figure 1.9). [40, 41]
Herein, five representative sialyltransferase inhibitors are presented below to highlight
the structural diversity of sialyltransferase inhibitors.

Donor analogues
The rational design of sialyltransferase donor inhibitors is to mimic the structure
of the natural donor, CMP-Neu5Ac (8) (Km= 46 µM), to bind to the active site and
competitively inhibit the enzyme. These kind of inhibitors usually contain a cytidine
moiety, which has been proven to play an essential role in enzyme binding.[42] The
cytidine nucleotides (cytidine monophosphate CMP, cytidine diphosphate CDP, and
cytidine triphosphate CTP) showed strong inhibitory ability (Ki = 16 to 50 µM),
which suggests the phosphate bridge between CMP and the sialyl group contributes
12
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largely to the binding to the active site of the enzyme. Due to the importance of the
phosphate bridge in binding to the enzyme, replacement of the phosphate with a
phosphite or phosphonate group slows down the cleavage of the glycosidic bond,
which leads to glycosyl transfer inhibition.[43] In 1998, CMP-quinic acid (9) was
developed by Schaub et al. as a CMP-Neu5Ac analogue by replacing the sialic acid
residue with quinic acid. The analogue (9) also exhibited an identical affinity to the
enzyme (eg. (9): Ki= 44 µM vs. (8): Km= 46 µM), which suggested the complete
Neu5Ac moiety may not be essential for high binding affinities.[21]

Transition-state analogues
A more potent class of sialyltransferase inhibitor was designed by Schmidt’s
group to mimic the transition-state (CMP-Neu5Ac≠) based on the proposed
mechanism shown in Figure 1.6. Of these, the transition-state analogue (10) prepared
by Skropeta et al. has proven to be one of the most potent inhibitors of α-2,6sialyltransferase (Ki= 0.07/0.3 µM).[20] More structure-activity relationship studies
and conformational analysis will be explained in detail in the following section.

Natural products
Soyasaponin I is a rigid pentacyclic system with a trisaccharide appended to it,
and is isolated from soyabeans. Early research has shown its competitive inhibition
(Ki= 2.1 µM) against α-2,3-sialyltransferase.[40] In addition to improved cell
permeability,

this

compound

was

shown

to

exhibit

effects

relating

to

invasive/metastatic behaviours of cancer cell lines.[44] Consequently, because of the
difficulty of obtaining a large amount of soyasaponin I, a series of lithocholic acid
analogues which were derived from soyasaponin I, were designed and prepared by
Chang et al. Biological evaluation against rat α-2,3-sialyltransferase showed potent,
non-competitive inhibition activity (IC50= 5-100 µM).[41] One of these lithocholic
acid derivatives, was found to inhibit migration and invasion abilities in various
13
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cancer cell lines and showed inhibitory activity of human umbilical vein endothelial
cells. Moreover, in both experimental and spontaneous metastasis assays with animal
models, the lithocholic acid derivative suppressed cancer cell metastasis.[15] Later,
Chiang et al. reported the cell-permeable derivative AL-10 (11) by peptide side-chain
modification from lithocholic acid. In preliminary assays, the derivative AL-10 (11)
displayed promising inhibition activity against both α-2,3-sialyltransferase (IC50=
0.88 µM) and α-2,6-sialyltransferase (IC50= 1.50 µM). This compound was further
subjected to animal studies, where the compound shows no cytotoxicity but inhibits
adhesion, migration, and invasion of cancer cells. More importantly, AL-10 (11)
significantly reduced experimental lung metastasis by 40% in vivo without affecting
on the liver and kidney of the experimental animals.[45]
Recently, several new bioactive natural compounds were shown to exhibit
enzyme inhibition activity against sialyltransferases, such as the flavonoid derivative
(12) reported by Hidari et al. [46], the marine metabolite isomalyngamide A [47] and
spirocyclic drimanes isolated from the fungus Stachybotrys cylindrospora.[48]
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Figure 1.9 Reported sialyltransferase inhibitors.

1.5.2 Sialyltransferase transition-state analogue inhibitors
Based on the proposed SN1-like sialyl transfer mechanism reported by Horenstein
et al.,[18] a strategy of developing analogues to mimic the transition-state (CMPNeu5Ac≠) was applied by Schmidt’s group. This was also based on kinetic studies,
which showed that transition-state analogues bind 107 to 105 times tighter to the
enzyme than the substrate in the ground state.[49] It can also be seen that from all the
various classes of sialyltransferase inhibitors described to-date, transition-state
analogue inhibitors have been the most successful.
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Two of the main characteristics of the transition-state (CMP-Neu5Ac≠) are partial
dissociation of the CMP moiety and the formation of a planar oxocarbenium ion in the
transition state, with the anomeric center (C-2) being trigonal planar, thus favoring the
coplanarity of the oxocarbenium ion assumed for the SN1-type transition-state. Based
on these characteristics, researchers from Schmidt’s group introduced a methine group
between the anomeric centre (C2) and the CMP leaving group to increase the distance
in the transition-state model and mimic the process of bond cleavage (see Figure
1.10). [19, 20, 50, 51]

Figure 1.10 Comparison of CMP-Neu5Ac≠ and its analogue.

Schmidt’s group has made a major contribution to the development and
optimisation of sialyltransferase transition-state analogue inhibitors. In 1998, Amann
et al. reported the transition-state analogue (13), which contained a phosphonate
group to replace the carboxylic group in the natural donor, where the phosphonate and
the phosphate negative charges were separated by five bonds (see Figure 1.11). A
second negative centre close to the CMP residue is required for binding to the active
site of the enzyme, as evidenced by CDP acting as a strong competitive
sialyltransferase inhibitor (Ki= 0.19 µM) as described previously. Moreover, this
analogue was shown to bind to α-2,6-sialyltransferase in the nanomolar range (Ki=
0.35 µM) compared with the natural donor, CMP-Neu5Ac (8) (Km= 46 µM), which
proved the merit of the transition-state analogue inhibitor strategy.[19] Muller et al.
designed and prepared derivatives with different side chains but retaining the Neu5Ac
16
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core and these modified compounds retained activity. Among these derivatives, the
neuraminic phenyl derivative (14) exhibited strong binding affinities (Ki= 0.029 µM)
to the ST enzyme.[51] Later on, the sialic acid residue was replaced by flat aryl or
hetaryl rings to improve access to the compounds. A wide range of aryl and hetaryl
derivatives were prepared and evaluated previously and shown to exhibit good
affinities to the sialyltransferase enzyme, among which the phenoxyphenyl derivative
(10) reported by Skopeta et al. displayed a similar high affinity to the enzyme as the
original Neu5Ac, but was more readily synthetically accessible.[20] More recently,
Mathew et al. reported the preparation of novel sialyltransferase inhibitors, replacing
the sialic residue with hetaryl rings such as thiazole, benzothiazole, benzoxazole,
benzothiophene and thiophene, however, their biological evaluation was not yet
reported.[52]
Replacement of the sialic residue with simple aryl rings was proven to increase
preparation accessibility and offer equivalent or even more potent sialyltransferase
inhibition activity to Neu5Ac containing examples. Therefore, in this project, it was
proposed to introduce functional groups such as electron-withdrawing groups,
electron-donating groups, halogen groups and alkyl groups on the phenyl rings to
develop further novel sialyltransferase transition-state analogue inhibitors 15a-i, for
structure-activity studies and for further biological evaluation (see Figure 1.11).

Figure 1.11 Modification of sialyltransferase transition-state analogue inhibitor.
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From structure-activity relationship studies and conformational analysis [19, 20,
43, 49-51], it has become apparent that the essential components of potent
sialyltransferase transition-state analogue inhibitors are (see Figure 1.12):
(i)

the neuraminyl sugar residue can be replaced with various aryl and
hetaryl moieties;

(ii)

the phosphate linkage is important for binding;

(iii)

a planar anomeric carbon is essential;

(iv)

an uncharged cytidine is essential;

(v)

there are at least two negative charges separated by five bonds;

(vi)

and the carboxyl group can be replaced by a phosphonate moiety to
increase activity.

Figure 1.12 Essential components of potent sialyltransferase transition-state analogue inhibitors.

Based on the above analysis, a series of new target compounds were designed to
obtain a thorough understanding of the structure-activity relationship of this kind of
inhibitor for further optimisation. Herein, our target novel compounds 15a-i shared
the basic structure shown in Figure 1.10. It was decided to choose electronwithdrawing groups such as (-NO2) and electron-donating groups such as (-OMe)
attached on the aromatic ring, to assess the electronic effects on enzyme affinity.
Moreover, analogues with halogens or alkyl groups at the 2, 3, and 4-substitution
position are designed and prepared for comparing affinities.
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1.6 Synthetic pathways for the synthesis of sialyltransferase
transition-state analogue inhibitors
1.6.1 Classical phosphoramidite approach
The classical pathway for preparation of sialyltransferase inhibitors has been by
the phosphoramidite approach, which gives two basic fragments: a diethyl or dibenzyl
α-hydroxyphosphonate 16a-i or 17a-i moiety, and a protected cytidine (18). The
phosphoryl linkage is formed by employing a phosphorylating reagent (such as 2cyanoethyl N,N,N’,N’-tetraisopropylphosphorodiamidite 19). Generally, the protected
cytidine (such as tri-acetylated cytidine 18) reacts with a phosphorylating reagent in
the presence of 1H-tetrazole (20) as an activator, generating a 2-cyanoethyl-2’,3’O,N4-triacetylcytidin-5’-yl-N,N-diisopropylphosphoramidite

21

(5’-amdite).

Consequently, the 5’-amidite (21) reacts with the α-hydroxyphosphonate moiety 16a-i
or 17a-i, followed by oxidation and hydrolysis, to generate the desired transition-state
analogues (see Figure 1.13).[19, 20, 50, 51, 53]

Figure 1.13 Retrosynthetic analysis of sialyltransferase transition-state analogue inhibitors via a
phosphoramidite approach.

The key α-hydroxyphosphonate fragment and their analogous phosphonic acids
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are well known important bioactive compounds, due to their mimicry of natural
hydroxycarboxylic groups.[54, 55] Herein, a series of α-hydroxyphosphonate
derivatives containing a range of electron-donating and electron-withdrawing
substituents are designed and prepared for assessing electronic effects on the
bioactivity of the α-hydroxyphosphonates, and also as key components of the target
sialyltransferase inhibitors. These α-hydroxyphosphonate compounds (16a-i or 17a-i)
will be assessed for protein kinase A (PKA) inhibition activity.
2-Cyanoethyl
reagent)

N,N,N’,N’-tetraisopropylphosphordiamidite
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(bis-amidite

is a widely used phosphorylating reagent in oligonucleotide analogues

synthesis. Comparing with other reported phosphorylating reagent, it is cheaper and
more stable towards hydrolysis and oxidation and successfully used in previous
sialyltransferase

transition-state

analogue

preparation.[19,

20]

But

this

phosphorylating reagent is less reactive and requires the use of activators such as 1Htetrazole.
1H-Tetrazole (20) is a four-nitrogen heterocycle and it is widely used in organic
synthesis due to it being a highly effective activator of phosphoramidite coupling. All
previous preparations of transition-state analogue inhibitors all employed 1H-tetrazole
(20) as the activator. However, it has been reported to be toxic and explosive upon
heating or heavy impact, and it is not available in Australia. Therefore, to find safe
and highly efficient tetrazole alternatives as activators to catalyse the coupling of the
two fragments turned out to be a crucial part of this project.

1.6.2 Proposed phosphotriester approach
After careful analysis of reported oligonucleotide derivative syntheses via a
phosphotriester approach [56-58], a new, concise and efficient approach was proposed
based on the structure of the novel sialyltransferase inhibitors 15a-i. The novel
sialyltransferase inhibitors 15a-i are regarded as a kind of phosphate diester
derivative, which has a protected cytidine (18) as a synthon, and a α20
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hydroxyphosphonate derivative (17a-i) as the other synthon linked with a phosphoryl
group. Therefore, in the proposed phosphotriester approach, the three hydroxyl groups
in anhydrous benzyl alcohol (24), dibenzyl α-hydroxyphosphonate (17a-i) and triN/O-acetylated cytidine (18) will react with the phosphorylating reagent PCl3 (23)
step by step in the presence of base, generating the phosphite triester intermediate,
followed by oxidation from the phosphite to the phosphate triester 22a-i. The desired
novel sialyltransferase inhibitors 15a-i will be prepared by deprotection of the acetyl
and benzyl protecting groups (see Figure 1.14).

Figure 1.14 Retrosynthetic analysis of sialyltransferase transition-state analogue inhibitors via a
phosphotriester approach.

The phosphorylating reagent PCl3 (23) is a very common reagent, readily
available, of low cost and highly reactive. Therefore, trials employing PCl3 according
to the proposed phosphotriester approach will be performed to prepare novel
sialyltransferase transition-state analogue inhibitors via a new and more concise
method.
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1.7 Aims of this project
Thus, the aims of this project are to:


Prepare a series of α-hydroxyphosphonate derivatives (Chapter 2).



Preform a large-scale synthesis of an appropriately protected cytidine
fragment for the coupling reactions (Chapter 3).



Synthesise a novel series of sialyltransferase transition-state analogue
inhibitors via a classical phosphoramidite approach (Chapter 4, Part A).



Develop a new methodology for the above synthesis using safer alternative
activators in place of 1H-tetrazole (Chapter 4).



Explore a new approach towards sialyltransferase transition-state analogue
inhibitors using a phosphotriester approach (Chapter 4, Part B).



If time permits, biological evaluation of both the α-hydroxyphosphonate
derivatives and the target sialyltransferase transition-state analogue inhibitors.
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2 CHAPTER 2
Synthesis of α-Hydroxyphosphonate Derivatives
2.1 Initial synthetic targets
2.1.1 Hydroxyphosphonate derivatives
α-Hydroxyphosphonates and their analogous phosphonic acids (e.g. Figure 2.1)
inhibit a variety of enzymes which react with hydroxycarboxylic groups, and exhibit a
wide range of biological activities, including anti-osteoporosis, anticancer,
antibacterial and antimalarial. [59-62] For example, 1-naphthylmethylphosphonic acid
(25) was prepared by McGeary and his colleagues to inhibit the enzyme purple acid
phosphatase, which has been proven as an osteoporosis treatment target.[59] The αhydroxyphosphonic acid derivative (26), which was synthesized and evaluated by
Kategaonkar et al., showed significant antimicrobial activity against E. coli and B.
subtilis.[60] The α-hydroxyphosphonic acid analogue (27) developed by Jiang et al.
showed potent activity against autotaxin, which is a therapeutic target for inhibiting
angiogenesis, invasion and migration of cancer cells.[61] Derivatives such as the nitro
α-hydroxyphosphonic acid derivative (28) shown in Figure 2.1 were prepared and
screened as inhibitors of CD-45 tyrosine phosphatase, which is a regulator of the
signal transduction process in haematopoetic cells.[62]
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Figure 2.1 Selected examples of bioactive α-hydroxyphosphonic acids.

2.1.2 α-Hydroxyphosphonates and phosphonic acids
α-Hydroxyphosphonates are one of the two key fragments of the novel
sialyltransferase inhibitors being developed and described herein. Additionally, αhydroxyphosphonates themselves are bioactive molecules as described previously.
Therefore, a series of nine diethyl α-hydroxyphosphonate derivatives 16a-i and nine
dibenzyl α-hydroxyphosphonate derivatives 17a-i were synthesized (Figure 2.2).
These derivatives contained a range of electron-donating and electron-withdrawing
substituents to be able to assess electronic effects on bioactivity of both the αhydroxyphosphonates and of the target sialyltransferase inhibitors. In addition, to
compare the potency of the free acid group, a deprotected phosphonic acid (29) was
also generated (Figure 2.2). The biological activity of selected examples from these
compounds was evaluated and is presented in Chapter 5.

Figure 2.2 Synthetic targets in this chapter (see Table 2.2 at the end of this chapter for full structures).
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2.2 Synthesis of diethyl α-hydroxyphosphonate derivatives
2.2.1 Chosen synthesis method
2.2.1.1 Non-selective synthesis of racemic α-hydroxyphosphonate derivatives
The main approach for the preparation of α-hydroxyphosphonate derivatives is
the phosphorylation of carbonyl compounds.[63, 64] Herein, four representative
methods were selected for comparison. Pandi et al. reported a simple, inexpensive
method to prepare racemic diethyl α-hydroxyphosphonates, where diethyl phosphite
was added to aromatic aldehydes in THF using Ba(OH)2·8H2O as a catalyst,
followed by stirring for 15 minutes at room temperature. After the reaction was
complete, the THF was removed under reduced pressure, and the residue was purified
by silica gel column chromatography (see Table 2.1, Entry 1).[65] Alternatively,
complexes containing lanthanide metals have been widely reported for catalysed
hydrophosphonylation of aromatic aldehydes.[66, 67] In 2012, Zhou et al. discovered
lanthanide amido complexes containing a calix[4]-pyrrolyl ligand as efficient
catalysts, for preparing diethyl α-hydroxyphosphonates from aldehydes and diethyl
phosphite in good yields. After reaction completion, the residue was extracted with
ethyl acetate and the final product was further purified by continuous washing with
hexane (see Table 2.1, Entry 2).[67]
In 2010, Mandhane and his colleagues explored an eco-friendly and convenient
approach for synthesis of diethyl α-hydroxyphosphonates. Various aldehydes were
reacted with triethyl phosphite in the presence of KH2PO4 under ultrasound-assisted,
solvent-free conditions at room temperature over 5-45 minutes. After the reaction was
complete, the desired compounds were isolated by extraction with ethyl acetate, and
solvent concentration afterwards, avoiding the need for silica column chromatography
(see Table 2.1, Entry 3).[68] In addition, a straightforward synthetic method was
generated by Wong et al., where triethylamine was added to a mixture of diethyl
phosphite and benzylaldehyde, which was stirred at room temperature overnight
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under solvent free conditions. The white precipitated product was purified by
recrystallization from diethyl ether (see Table 2.1, Entry 4).[69] After comparison of
these four methods, Wong’s straightforward approach was finally chosen due to
reagent accessibility, high efficiency, ease of work-up and relatively low cost.

Table 2.1 Reported methods for the preparation of diethyl α-hydroxyphosphonate derivatives.

Entry

Reactants

Catalyst

Solvent

Conditions

Purification

1

diethylphosphite

Ba(OH)2·8H2O

THF

RT, 15 min

2

diethylphosphite

THF

RT, 20 min

3

triethylphosphite

Lanthanide
amido complexes
KH2PO4

-

4

diethylphosphite

Et3N

-

ultrasound
irradiation,
RT, 5-45 min
RT, 18 hours

Column
chromatography
Extraction,
hexane wash
Extraction
Recrystallization

Yield
(%)
72-99
71-99
80-94
86

2.2.1.2 Asymmetric synthesis of α-hydroxyphosphonate derivatives
α-Hydroxyphosphonate derivatives, which contain a chiral centre, have showed
various biological activity ascribed to the different absolute configurations. Thus, over
the last 15 years, several reports on the synthesis of chiral α-hydroxyphosphonates
have appeared. In 2005, Kolodiazhnyi reviewed the different pathways used for
asymmetric synthesis of α-hydroxyphosphonates, which included asymmetric
reduction of ketophosphonates, the asymmetric oxidation of carbon-carbon bonds,
chemoenzymatic synthesis and asymmetric addition (see Figure 2.3).[70]
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Figure 2.3 General routes for the asymmetric synthesis of α-hydroxyphosphonates.

One of the stereoselective pathways of α-hydroxyphosphonate preparation
previously described by our research group is the enantioselective oxidation of
benzylphosphonates with chiral oxaziridines (see Scheme 2.1). Diethyl and diallyl
benzylphosphonates were first reacted with NaHMDS at -78 oC for 20 minutes in
THF, generating phosphoryl-stabilised anions, which were then reacted with
enantiopure (+)-8,8-(dichlorocamphor)sulfonyloxaziridine under the same conditions
for three hours, generating the desired chiral non-racemic (S)-enantiomers in good
yields and high enantiomeric excess. Correspondingly, the (R)-enantiomers were
prepared

by

the

same

method

utilising

(-)-8,8-(dichlorocamphor)

eq.),

-78

sulfonyloxaziridine.[71]

Reagents

and

conditions:

(i)

NaHMDS

(1.5

THF,

o

C,

20

min;

(+)-8,8-

o

(dichlorocamphor)sulfonyloxaziridine (2 eq.), -78 C, 3h, 25-45%, 86-99% ee.
Scheme 2.1 Asymmetric synthesis of α-hydroxyphosphonates via enantioselective oxidation.

However, the enantiopure sialyltransferase inhibitors, which were prepared from
their corresponding chiral, non-racemic α-hydroxyphosphonates via phosphoramidite
coupling, didn’t show significant difference in enzyme affinity. Both the R and S
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isomers showed a potent affinity against α-(2,6)-sialyltransferase, and there was no
direct relationship observed between absolute configuration and affinity. For example,
for the phenyl derivative (15a) shown in Figure 2.4, the (S)-enantiomer was 4-times
more active than the (R)-enantiomer, but for the 3-phenoxyphenyl derivative (10) the
reverse was true.[20]
Ar
(R)-phenyl (15a)

Ki(µM)
0.8 ± 0.2

(S)-phenyl (15a)

0.2 ± 0.02

(R)-3-phenoxyphenyl (10)

0.07 ± 0.01

(S)-3-phenoxyphenyl (10)

0.3 ± 0.1

Figure 2.4 Inhibition constants of enantiopure sialyltransferase inhibitors against α-(2,6)sialyltransferase.

Therefore, in our current study chiral α-hydroxyphosphonates were not needed
and racemic diethyl α-hydroxyphosphonate derivatives 16a-i were instead prepared in
a relatively cheap and efficient manner. Commercially available aldehydes were
reacted with diethylphosphite, employing triethylamine as the base, to generate the
desired racemic diethyl α-hydroxyphosphonate derivatives 16a-i (see Figure 2.2,
Table 2.2) as described by Wong et al. All of these reactions were monitored by TLC.
Compound 16a was purified by recrystallization from diethyl ether as described in the
literature.[69] Instead of trying to find the appropriate solvents for recrystallization for
the novel compounds, compounds 16b-i were purified according to Zhou’s method,
where the residue was poured into a small amount of water, then extracted with ethyl
acetate, the ethyl acetate layer was collected and concentrated, and the final product
was purified by repeated washing with hexane.[67] Compound 16f still contained
some by-product after washing, and was therefore further purified by silica column
chromatography. Detailed descriptions of the synthesis of each compound appear
below.
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2.2.2 Synthesis and characterisation
derivatives 16a-i

of

diethyl

α-hydroxyphosphonate

2.2.2.1 Synthesis of p-substituted diethyl α-hydroxyphosphonate derivatives
16a, 16b, 16c

Reagents and conditions: (i) Diethylphosphonate (1.1 eq.), Et3N (2.2 eq.), RT, 16 h, 16a=72%,
16b=78%, 16c=95%.
Scheme 2.2 Synthesis of benzylphosphonate 16a, tolylphosphonate 16b and 4-ethylbenzylphosphonate
16c.

The

known

benzylphosphonate

16a,

tolylphosphonate

16b

and

4-

ethylbenzylphosphonate 16c were synthesized in good to excellent yields via Wong’s
method described earlier.[69] The structure of the benzylphosphonate 16a, which was
obtained as a white solid, was confirmed through 1H NMR spectroscopy, with
aromatic protons observed as a multiplet between 7.3-7.5 ppm with an integration of
five protons. Moreover, a doublet (2JP-H = 10.5 Hz) due to proton-phosphorus
coupling appearing at 5.0 ppm with an integration of one proton was ascribed to the
α-carbon proton (CHOH). Furthermore, a triplet (J = 7.0 Hz) with an integration of
six protons was observed at 1.2 ppm, corresponding to the methyl protons in the
diethyl groups. A distinctive multiplet with an integration of four protons observed at
3.9-4.0 ppm, was ascribed to the methylene protons in the diethyl groups. The typical
pattern for an ethyl group is a mutually coupled triplet and quartet. However, the
signal is slightly complicated here due to the additional coupling to phosphorus,
giving rise to a multiplet. MS revealed a molecular ion at m/z 267, corresponding to
the M + Na+ peak in the ESI+ spectrum, for the formula C11H17NaO4P. Both the
spectral and physical data matched those reported.[69]
The structures of the white solids 16b and 16c were also confirmed through 1H
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NMR spectroscopy. The diethyl groups were identified as described above and the αcarbon proton was observed as a doublet (2JP-H = 11.0 Hz) at 5.0 ppm. The aromatic
protons appeared at 7.2-7.4 ppm with an integration of four protons. A singlet at 2.3
ppm with an integration of three protons was observed corresponding to the methyl
group substituted on the benzene ring of 16b. While an additional coupled triplet and
quartet with an integration of three and two protons at 1.3 ppm and 2.7 ppm
respectively were observed corresponding to the p-ethyl group substituted on the
benzene ring of 16c. All spectral data matched those reported.[65, 72] In addition,
evaluation of their mass spectra revealed a molecular peak for 16b and 16c at m/z 281
and 295, corresponding to the formulae C12H19NaO4P and C13H21NaO4P, respectively.
2.2.2.2 Synthesis of diethyl 3,5-dimethoxybenzyl(hydroxy)phosphonate 16d

Reagents and conditions: (i) Diethylphosphonate (1.1 eq.), Et3N (2.2 eq.), RT, 16 h, 84%.
Scheme 2.3 Synthesis of 3,5-dimethoxybenzylphosphonate 16d.

The known 3,5-dimethoxybenzylphosphonate 16d was also prepared according to
the method of Wong et al.[69] A triplet (J = 7 Hz) and a multiplet with an integration
of six and four protons respectively at 1.2 ppm and 3.9-4.0 ppm, and a doublet at 5.0
ppm were firstly identified as the diethyl group and α-carbon proton respectively.
Highly shielded aromatic protons with an integration of three protons appeared at 6.46.7 ppm due to the electron-donating methoxy groups. A singlet which appeared at 3.8
ppm with an integration of six protons was ascribed to the two methoxy group
protons. The compound 16d was also identified by MS examination, where a strong
M + Na+ peak in the ESI+ spectrum appeared at m/z= 327, corresponding to the
formula C13H21NaO6P. Both the spectral and physical data matched those
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reported.[73]
2.2.2.3 Synthesis of diethyl 3-nitrobenzyl(hydroxy)phosphonate 16e

Reagents and conditions: (i) Diethylphosphonate (1.1 eq.), Et3N (2.2 eq.), RT, 16 h, 94%.
Scheme 2.4 Synthesis of 3-nitrobenzylphosphonate 16e.

The known 3-nitrobenzylphosphonate derivative 16e was also prepared according
to the method of Wong et al.[69] The structure of the light yellow solid was confirmed
though 1H NMR spectroscopy. The diethyl group and α-carbon proton were identified
from peaks at 1.2 ppm, 4.1-4.2 ppm and 5.1 ppm respectively, as described
previously. Aromatic protons with an integration of four were observed downfield at
7.5-8.4 ppm due to the electron-withdrawing, meta-substituted nitro group. Moreover,
a strong M + Na+ peak appeared at an m/z= 312 value in the ESI+ spectrum, which
also confirmed the formation of 16e. Both the spectral and physical data matched
those reported.[66]
2.2.2.4 Synthesis of diethyl 3-hydroxybenzyl(hydroxy)phosphonate 16f

Reagents and conditions: (i) Diethylphosphonate (1.1 eq.), Et3N (2.2 eq.), RT, 16 h, 92%.
Scheme 2.5 Synthesis of 3-hydroxybenzylphosphonate 16f.

The known 3-hydroxybenzylphosphonate 16f was also prepared according to the
method of Wong et al.[69] 1H NMR spectroscopy revealed a triplet (J = 7.0 Hz) and a
multiplet with an integration of six and four protons at 1.2 ppm and 3.8-4.1 ppm, and
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a doublet at 5.0 ppm corresponding to the diethyl groups and α-carbon proton
respectively. A distinctive singlet that appeared at 8.0 ppm with an integration of one
protons was ascribed to the hydroxyl proton attached on the benzene ring. The benzyl
aromatic protons appeared as mutiplets between 6.7-7.3 ppm with an integration of
four protons. A strong peak for the M + Na+ ion at m/z= 283 in the ESI+ spectrum,
corresponding to the formula C11H17NaO5P, indicated the formation of 16f as well.
Both the spectral and physical data matched those reported.[68, 74]
2.2.2.5 Synthesis of diethyl fluorobenzyl(hydroxy)phosphonates 16g, 16h and 16i

Reagents and conditions: (i) Diethylphosphonate (1.1 eq.), Et3N (2.2 eq.), RT, 16 h, 16g=92%,
16h=95%, 16i=94%.
Scheme 2.6 Synthesis of diethyl 2-, 3- and 4-fluorobenzylphosphonate derivatives.

The diethyl 2-, 3- and 4-fluorobenzylphosphonate derivatives 16g, 16h and 16i
were synthesized in excellent yields via Wong’s method.[69] The mass spectra of
these three isomers all displayed strong M + Na+ peaks at m/z= 283 in the ESI+
spectrum, corresponding to the expected formula of C11H16FNaO4P. 1H NMR
spectroscopy of these three compounds was similar, and the diethyl protons and αcarbon proton were identified from peaks at 1.2 ppm, 4.0-4.1 ppm and 5.1 ppm,
respectively as described previously. For the novel 2-fluorobenzylphosphonate
derivative 16g, a large doublet (1JF-C = 245.6 Hz) due to fluorine-carbon coupling
appeared at 159.8 ppm in the

13

C NMR spectrum and was ascribed to the aromatic

quaternary carbon (C2) bearing the fluorine atom. The other aromatic quaternary
carbon (C1) appeared at 124.6 ppm and was identified from a doublet (2JF-C = 13.4
Hz) due to the smaller fluorine-carbon coupling. Similarly, the aromatic methine
carbon C3 was observed form a doublet (2JF-C = 22.0 Hz) that appeared at 114.9 ppm.
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Three peaks were observed between 124.2-129.6 ppm, corresponding to the other four
aromatic carbons (C4, C5 and C6). A doublet (1JP-C = 164.4 Hz) due to phosphoruscarbon coupling appeared at 64.1 ppm and was ascribed to the α-carbon (C7). Two
doublets (2JP-C = 7.6 Hz) due to phosphorus-carbon coupling appeared at 63.4 ppm
and 63.1 ppm respectively, were ascribed to the two methylene carbons (C8 and C10).
Two singlets appeared at 16.2 ppm and 16.1 ppm respectively, and were ascribed to
the two methyl carbons (C9 and C11) (see Figure 2.5). Analysis of 16g by high
resolution electrospray ionisation spectrometry (HRESI-MS) resulted in a protonated
molecular ion of m/z 263.0847, consistent with the protonated molecular formula of
C11H17FO4P [M+H]+.

Figure 2.5 13C NMR of the novel 2-fluorobenzylphosphonate derivative 16g.

At the commencement of the project, the 3-F & 4-F derivatives 16h and 16i were
not yet reported in the literature. However, during the course of the project, these two
compounds appeared in a newly published paper, [65] although, their NMR data were
not fully assigned. Herein, the two isomers 16h and 16i were further distinguished
from 16g by their different aromatic splitting patterns (see Figure 2.6).
For the 3-fluorophenylphosphonate derivative 16h, a doublet of doublets with an
integration of one proton appeared at 7.0 ppm, and was ascribed to H2. Moreover, H1,
H3 and H4 were observed as overlapping multiplets between 7.2-7.4 ppm due to
proton-fluorine coupling with an integration of three protons.
For the 4-fluorophenylphosphonate derivative 16i, the chemically equivalent
protons H2 and H3 were observed as an overlapping doublet of doublet (J = 9 Hz, 3JF-H
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= 9 Hz) with an integration of two protons at 7.1 ppm due to the shielding effect of
the neighbouring fluorine. While the other equivalent protons H1 and H4 appeared as a
doublet of doublets (J = 9 Hz, 4JF-H = 6 Hz) at 7.5 ppm with an integration of two
protons due to proton-fluorine coupling.

Figure 2.6 Aromatic proton splitting patterns of 3- and 4-fluorophenylphosphonate derivatives 16h &
16i.

2.3 Synthesis of dibenzyl α-hydroxyphosphonate derivatives
2.3.1 Chosen synthetic method
Based on the experience of preparing the diethyl α-hydroxyphosphonates 16a-i,
the dibenzyl α-hydroxyphosphonate derivatives 17a-i were synthesized in the same
manner (Figure 2.2). However, instead of setting up a solvent-free reaction,
dichloromethane (DCM) was chosen as the preferred solvent for reaction completion,
due to the non-polar properties of the expected products. The dibenzyl αhydroxyphosphonate derivatives 17a-i are more non-polar than the analogues diethyl
α-hydroxyphosphonates 16a-i. For this reason, DCM was also used to substitute ethyl
acetate to extract the products 17a-i from the aqueous layer after the reaction. The
DCM layer was collected and concentrated, and the final product was further purified
by repeated washing with hexane as mentioned previously.[67] However, derivatives
17b and 17f were not isolated in a purified form due to time restraints.
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2.3.2 Synthesis and characterisation of dibenzyl α-hydroxyphosphonate
derivatives 17a-i
2.3.2.1 Synthesis of dibenzyl α-hydroxyphosphonate derivatives 17a & 17c

Reagents and conditions: (i) Dibenzylphosphonate (1.1 eq.), Et3N (2.2 eq.), DCM, RT, 16 h, 17a=88%,
16c=88%.
Scheme 2.7 Synthesis of benzylphosphonate 17a and 4-ethylbenzylphosphonate 17c.

The structure of the α-hydroxybenzylphosphonate 17a was confirmed by 1H
NMR spectroscopy, with a distinctive multiplet with an integration of four protons
observed at 4.8-4.9 ppm, corresponding to the methylene protons in the benzyl
groups. The α-carbon proton was also evident from the doublet of doublets at 5.0 ppm
with an integration of one proton. In addition, a broad multiplet at 7.2-7.5 ppm with
an overall integration of fifteen was ascribed to the aromatic protons, from both the
benzyl aldehyde component and from the two benzyl protecting groups. A strong M +
Na+ peak at m/z= 391 in the ESI+ spectrum, corresponding to the formula
C21H21O4PNa, further confirmed the formation of 17a, and all the spectral and
physical data matched those reported.[75]
The novel dibenzyl 4-ethylbenzylphosphonate 17c was prepared in good yield
(88%) via the standard method. The structure of the white solid 17c was confirmed
though 1H NMR spectrum, where a coupled triplet and quartet (J = 7.0 Hz) with an
integration of three and two protons respectively was observed at 1.2 ppm and 2.6
ppm, corresponding to the p-ethyl group substituted on the benzene ring. Moreover,
the methylene protons and α-carbon proton were distinguished from a multiplet with
an integration of four protons at 4.8-4.9 ppm and a doublet at 5.0 ppm, respectively. In
the

13

C NMR spectrum of 17c, two singlets appeared at 144.6 ppm and 133.6 ppm,
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and were ascribed to the aromatic quaternary carbons (C4) and (C1), respectively. The
two quaternary carbons (C9, C16) in the benzyl aromatic rings were observed as two
singlets at 136.4 ppm and 136.3 ppm, respectively. The other 14 aromatic protons
were identified from signals between 115.3-129.3 ppm. A doublet with a large
coupling constant (1JP-C = 158.8 Hz) due to one-bond phosphorus-carbon coupling
appeared at 70.8 ppm, and was ascribed to the α-carbon (C7). Two doublets (2JP-C =
7.5 Hz) appeared at 63.4 ppm and 63.1 ppm respectively, corresponding to the two
methylene carbons (C8 and C15). Two singlets that appeared at 28.8 ppm and 15.8
ppm were ascribed to the carbons in the ethyl group. Analysis by high resolution
electrospray ionisation spectrometry (HRESI-MS) resulted in a protonated molecular
ion of m/z 397.1565, consistent with the expected protonated molecular formula of
C23H26O4P [M+H]+.

2.3.2.2 Synthesis of dibenzyl 3,5-dimethoxylbenzyl(hydroxy)phosphonate 17d

Reagents and conditions: (i) Dibenzylphosphonate (1.1 eq.), Et3N (2.2 eq.), DCM, RT, 16 h, 92%.
Scheme 2.8 Synthesis of dibenzyl 3,5-dimethoxylbenzylphosphonate 17d.

The novel dibenzyl 3,5-dimethoxylphenylphosphonate 17d was prepared in
excellent yield (92%) via the standard method. According to the 1H NMR spectrum,
the α-carbon proton and methylene protons appeared at 4.9-5.0 ppm, aromatic protons
appeared in two areas, shielded at 6.4-6.6 ppm due to the methoxy groups with an
integration of three protons, and at 7.2-7.4 ppm with an integration of 10 protons for
the benzyl protecting groups. One singlet at 3.7 ppm with an integration of six protons
was identified to be the methoxy protons. In the
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appeared at 160.8 ppm, and was ascribed to the aromatic quaternary carbons (C3) and
(C5). The aromatic quaternary carbon (C1) was identified from the singlet at 138.9
ppm. Two quaternary carbons (C9, C16) in the benzyl aromatic rings were observed
as two singlets at 136.3 ppm and 136.2 ppm respectively. The other 13 aromatic
protons were identified from signals between 101.0.3-128.7 ppm. Similarly, a doublet
with a large coupling constant (1JP-C = 158.8 Hz) at 71.3 ppm was ascribed to the αcarbon (C7). Two doublets (2JP-C = 7.5 Hz) appeared at 68.9 ppm and 68.7 ppm
respectively, corresponding to the two methylene carbons (C8 and C15). A singlet
appeared at 55.5 ppm, and was ascribed to the two methoxy carbons. Analysis by high
resolution electrospray ionisation spectrometry (HRESI-MS) resulted in a molecular
ion of m/z 451.1307, consistent with the molecular formula of C23H25O6P [M + Na]+.

2.3.2.3 Synthesis of dibenzyl 3-nitrobenzyl(hydroxy)phosphonate 17e

Reagents and conditions: (i) Dibenzylphosphonate (1.1 eq.), Et3N (2.2 eq.), DCM, RT, 16 h, 76%.
Scheme 2.9 Synthesis of dibenzyl 3-nitrobenzylphosphonate 17e.

The structure of the light yellow solid obtained as 17e was identified by 1H NMR
spectroscopy. The methylene protons and α-carbon proton were firstly distinguished
from a multiplet with an integration of four protons at 4.8-5.0 ppm and a doublet at
5.1 ppm, respectively. Aromatic protons with an integration of 14 protons were
observed downfield at 7.3-8.3 ppm due to the deshielding effect of the metasubstituted nitro group. The spectral and physical data coincided with those
previously reported in the literature.[65] Moreover, a strong M + Na+ peak at m/z=
436 in the ESI+ spectrum, corresponding to the formula C21H20NO6PNa, further
confirmed the formation of 16e.
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2.3.2.4 Synthesis of dibenzyl fluorobenzyl(hydroxy)phosphonate 17g, 17h and
17i

Reagents and conditions: (i) Dibenzylphosphonate (1.1 eq.), Et3N (2.2 eq.), DCM, RT, 16 h, 17g=72%,
17h=73%, 17i=84%.
Scheme 2.10 Synthesis of dibenzyl 2-, 3-, 4-fluorobenzylphosphonate

The three novel dibenzyl 2-, 3-, 4-fluorophenylphosphonate derivatives 17g, 17h
and 17i were synthesized in good yields. Analysis of these three isomers by high
resolution electrospray ionisation spectrometry (HRESI-MS) all resulted in a
protonated molecular ion of m/z 387.1162, consistent with the protonated molecular
formula of C21H21FO4P [M+H]+.
The 1H NMR of 17g revealed methylene protons and a α-carbon proton at 4.8-5.0
ppm and 5.4 ppm, respectively. Aromatic signals with an integration of 14 protons
were also observed at 7.0-7.6 ppm. In the

13

C NMR spectrum (Figure 2.7), four

aromatic quaternary carbons were firstly identified, a doublet with a very large
coupling constant (1JF-C = 246.8 Hz) due to one bond fluorine-carbon coupling
appeared at 159.8 ppm, and was ascribed to the aromatic quaternary carbon (C2)
bearing the fluorine. The aromatic quaternary carbon (C1) was identified from a
doublet (2JF-C = 15.3 Hz) with a smaller fluorine-carbon coupling that appeared at
124.1 ppm. Two quaternary carbons (C9, C16) in the benzyl aromatic rings were
observed as two singles appeared at 136.0 ppm and 135.9 ppm respectively. The
aromatic carbon C3 was observed as a doublet (2JF-C = 20.0 Hz) appearing at 115.1
ppm. The other nine aromatic carbons gave rise to signals between 124.1-129.8 ppm.
Moreover, a doublet with a large coupling constant (1JP-C = 162.1 Hz) appeared at 64.2
ppm, corresponding to the α-carbon (C7). Two doublets (2JP-C = 6.3 Hz) due to
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phosphorus-carbon coupling appeared at 68.8 ppm and 68.5 ppm respectively, and
were ascribed to the two methylene carbons (C8 and C15) (see Figure 2.7).

Figure 2.7 13C NMR of the novel 2-fluorobenzylphosphonate derivative 17g.

Similarly, in the 1H NMR spectrum of 17h, the methylene protons and α-carbon
proton at 4.9-5.0 ppm and 5.1 ppm were firstly identified, along with multiplets with
an integration of 14 protons at 7.0-7.4 ppm corresponding to the three sets of aromatic
protons. Analysis by

13

C NMR also confirmed the structure (Figure 2.8). A doublet

with a very large coupling constant (1JF-C = 244.1 Hz) appeared at 162.7 ppm, and was
ascribed to the aromatic quaternary carbon (C3) bearing the fluorine atom. The other
aromatic quaternary carbon (C1) was identified from a doublet (3JF-C = 5.6 Hz) at
135.8 ppm. The two quaternary carbons (C9, C16) in the benzyl aromatic rings of the
phosphonate protecting groups were observed as two singlets that appeared at 136.0
ppm and 135.9 ppm respectively. The other 14 aromatic protons were identified from
signals at 114.1-129.7 ppm. Two methylene secondary carbons and the α-carbon
signal appeared at 63.5 ppm, 64.8 ppm and 74.5 ppm, respectively.
Additionally, 1H NMR spectroscopy of 17i revealed methylene protons and αcarbon proton peaks at 4.9-5.0 ppm, along with multiplets with an integration of 14
protons at 6.9-7.4 ppm corresponding to the aromatic protons. Analysis by 13C NMR
spectrum also confirmed the structure. A doublet (1JF-C = 245.2 Hz) that appeared at
162.8 ppm was ascribed to the aromatic quaternary carbon (C4) bearing the fluorine
atom. The other aromatic quaternary carbon (C1) was identified from a singlet at
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135.8 ppm. Two quaternary carbons (C9, C16) in the benzyl aromatic rings were
observed as two singles that appeared at 136.2 ppm and 136.1 ppm respectively. The
other 14 aromatic carbon signals at 115.4-129.2 ppm, and two methane secondary
carbons and the α-carbon signals were observed at 68.6 ppm, 68.8 ppm and 70.6 ppm,
respectively (see Figure 2.8).

Figure 2.8 Carbon splitting patterns of 3- and 4-fluorobenzylphosphonate derivatives 17h and 17i.

2.4 Synthesis of hydroxyl benzylphosphonic acid
The deprotected benzylphosphonic acid (29) was prepared for bioactivity
comparisons with the analogous diethyl benzylphosphonate 16a and dibenzyl
benzylphosphonate 17a. Earlier literature reported that benzylphosphonic acid (29)
can be prepared by either dealkylation from diethyl benzylphosphonate 16a with
TMSBr/TMSCl,[59, 76] or hydrogenation of 17a with 10%Pd-C as a catalyst under 1
atm of H2.[77] TMSBr and TMSCl are widely reported reagents for dealkylation.[59,
76, 78, 79] Herein, two approaches were tried to prepare the phosphonic acid (29)
from the corresponding diethyl benzylphosphonate 16a employing TMSBr and
TMSCl as deprotection reagents.
McGeary’s method was firstly used to generate benzylphosphonic acid (29).[59]
Chlorotrimethylsilane (TMSCl) and sodium iodide were added to a solution of diethyl
benzylphosphonate 16a in acetonitrile, stirring for four days at room temperature. The
progress of this reaction was monitored by TLC. After completion of the reaction, the
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concentrated residue was acidified with concentrated HCl, and then extracted with
ethyl acetate. However, only a poor yield was obtained due to the use of the less
reactive TMSCl. Next, benzylphosphonic acid (29) was prepared via Dayde’s
approach [76] in 40% yield utilising excess bromotrimethylsilane (TMSBr) as the
dealkylation reagent (see Scheme 2.11). The structure of phosphonic acid (29) was
confirmed through 1H NMR spectroscopy, which indicated the presence of the
aromatic protons from multiplets at 7.2-7.5 ppm with an integration of five protons
but the loss of the ethyl peaks. Moreover, a doublet appearing at 4.2 ppm with an
integration of one proton was ascribed to the α-carbon proton (CHOH). The mass
spectrum also revealed a strong M - H- peak at m/z 197 in ESI- spectrum,
corresponding to the formula C7H8O4P, which further confirmed the structure. The
spectral data and physical data coincided with those previously reported in the
literature.[80]

Reagents and conditions: (i) TMSBr (10 eq.), DCM, RT, 16 h, 40%.
Scheme 2.11 Synthesis of the phosphonic acid (29) from the corresponding phosphonate 16a.

2.5 Summary
This chapter reported the successful synthesis and characterisation of nine diethyl
α-hydroxyphosphonate derivatives 16a-i, nine dibenzyl α-hydroxyphosphonate
derivatives 17a-i and one hydroxyphosphonic acid (29), including six novel examples
(16g, 17c, 17d, 17g, 17h and 17i). In addition, a further two diethyl αhydroxyphosphonate derivatives (16h and 16i) were unknown at the commencement
of the project, but were described in the literature during the year. Two of the dibenzyl
derivatives (17b and 17f) were not isolated in pure form due to time restraints. Our
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developed approaches were concise and inexpensive and readily accessible, offering
comparable yields of products to those reported ranging from 72-95% (see Table 2.2).
The purification procedure we developed replaced almost all the silica column
chromatography purification often used in the literature for these types of compounds
by relatively low cost ethyl acetate or dichloromethane extraction and hexane
washing, which is quicker and easier than the reported methods.[65, 67, 68] In
addition, the α-hydroxyphosphonate derivatives 16c and 16h were obtained as a
colourless (m.p. 46-47oC) and a white solid (m.p. 58-59 oC), respectively, after
standing for three days, which is different from the reported physical appearance for
these two compounds as liquids.[65]

Table 2.2 α-Hydroxyphosphonate derivatives prepared and their yields.
Diethyl α-hydroxyphosphonate derivatives 16a-i
Dibenzyl α-hydroxyphosphonate derivatives 17a-i

16a R= H, 72%

17a R= H, 88%

16b R= 4-Me, 78%

17b R= 4-Me, 79% ≠

16c R= 4-Et, 95%

17c R= 4-Et, 88% +

16d R= 3,5-OMe,84%

17d R= 3,5-OMe, 92% +

16e R= 3-NO2, 94%

17e R= 3-NO2, 76%

16f R= 3-OH, 92%

17f R= 3-OH , 88% ≠

16g R= 2-F, 92% +

17g R= 2-F, 92% +

16h R= 3-F, 95%

17h R= 3-F, 95% +

16i R= 4-F, 94%

17i R= 4-F, 94% +

 Novel

≠ crude yield

All of these compounds described herein, were purified and characterized as key
fragments for a coupling reaction with a CMP moiety to generate novel
sialyltransferase transition-state inhibitors as described in Chapter 4. Evaluation of the
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protein kinase A inhibition activity of these α-hydroxyphosphonate derivatives is
presented in Chapter 5.
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3 CHAPTER 3
Synthesis of the Protected Cytidine Fragment
3.1 Synthesis of tri-N/O-acetylated cytidine
Based on structure-activity relationship studies of sialyltransferase inhibitors
shown in Figure 1.12, both the uncharged cytidine and phosphate linkage were
illustrated to be essential for binding. Thus, our designed sialyltransferase inhibitors
all include the essential cytidine monophosphate (CMP) component. According to the
classical phosphoramidite approach shown in Figure 1.13, 2-cyanoethyl-2’,3’-O,N4triacetylcytidin-5’-yl-N,N-diisopropylphosphoramidite (5’-amidite) 21 is the key
intermediate for the coupling of a diethyl or dibenzyl α-hydroxyphosphonate 16a-i or
17a-i moiety to generate the desired transition-state analogues 15a-i (discussed in the
next chapter). To generate the intermediate 5’-amidite (21), tri-N/O-acetylated
cytidine (18) bearing a free 5’-hydroxyl group was identified as the key precursor.
Herein, we give a detailed description of the preparation of the key precursor. TriN/O-acetylated cytidine (18) can be prepared from commercially available cytidine
via three steps: 1) selective primary alcohol protection, 2) acetylation of the secondary
alcohol and primary amine, and then 3) deprotection of the silyl protecting group to
obtain a free primary alcohol (see Figure 3.1).
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Figure 3.1 Retrosynthetic analysis of tri-N/O-acetylated cytidine (18).

3.1.1 Synthesis and characterisation of N4–acetyl-1-(2’,3’-di-O-acetyl-5’-O -tertbutyldimethylsilyl-β-D-arabinofuranosyl)cytosine (31)
3.1.1.1 Reported synthetic method
The selective silylation of the 5’-hydroxyl group of cytidine (30) can be achieved
through the use of bulky protecting groups such as tert-butyldimethylsilyl chloride
(TBDMSCl) (Scheme 3.1). TBDMSCl was chosen because it is stable up to 230 oC
and it is approximately 104 times more stable than the trimethylsilyl (TMS) group
towards basic hydrolysis.[81] Additionally, it is easy to be selectively cleaved in the
presence of tetrabutylammonium fluoride (TBAF).[82] The silyl protecting group
selectively reacts with a primary alcohol rather than a secondary alcohol due to steric
hindrance. Several bases and solvent were reported to be suitable for this
synthesis.[83-87] Herein, three representative methods reported to give excellent
yields of the desired product 31 were selected for comparison (see Table 3.1).
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Table 3.1 Different reported methods for preparation of silyl protected cytidine 31.
Entry
Reagent
Base
Solvent
Yield (%)
1
TBDMSCl
imidazole
Anh.pyridine
97
2
TBDMSCl
imidazole
DMF
91
3
TBDMSCl
Et3N (DMAP)
DMF, DCM
82
All reactions were performed at RT, overnight & products purified by column chromatography.

In the approach described by Cho et al., imidazole was added as base to a
solution of cytidine in anhydrous pyridine, generating the required product in
excellent yield after purification by silica column chromatography (Table 3.1, Entry
1).[83] According to the method developed by Debarge and his colleagues,
dimethylformamide (DMF) was used as a solvent and imidazole was employed as a
base, next, the desired compound was purified by column chromatography, also
giving an excellent yield of product (Table 3.1, Entry 2).[84] In 2010, Rodríguez et
al. synthesized the desired compound in good yield by using triethylamine as a base
and 4-dimethylaminopyridine (DMAP) as a catalyst in the presence of
dimethylformamide and dichloromethane (Table 3.1, Entry 3).[86]
4-Dimethylaminopyridine is well known as a catalyst for the esterification of
alcohols. The proposed mechanism pathway proceeds through nucleophilic attack of
DMAP at the TBDMS group and subsequent formation of the corresponding TBDMS
pyridinium/chloride salt. The 5’-hydroxyl group of cytidine then reacts with this salt
in the presence of triethylamine as an auxiliary base, providing the final product.[88,
89] The nucleophilic mechanism of the DMAP catalysed reaction is shown below (see
Figure 3.2).

Figure 3.2 Nucleophilic mechanism of DMAP catalysed selective protection of alcohols.
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3.1.1.2 Synthesis of selectively protected silylated cytidine (31)

Reagents and conditions: (i) tert-Butyldimethyl chloride (1.1 eq.), Et3N (1 eq.), DMAP (0.1 eq.), DMF,
room temperature, 16 h, 17-92%.
Scheme 3.1 Synthesis of selectively protected silylated cytidine 31.

Of the three methods, it was decided to avoid the use of pyridine, thus method 2
and method 3 were investigated. The method developed by Rodríguez et al. was
firstly used to prepare selectively protected silylated cytidine 31. Several attempts
were tried for condition optimisation to obtain a reasonable yield. Additionally, the
approaches discovered by Debarge et al. were also tried to prepare the desired
compound (see Table 3.2).

Table 3.2 Conditions trialled for synthesis of the selectively silyl protected cytidine 31.
Entry Reagent
Base
Solvent
Conditions
Work-up
1
TBDMSCl Et3N(DMAP)
DCM, DMF RT, 48h
DCM extraction
2
TBDMSCl Et3N(DMAP)
DMF
RT, overnight
DCM extraction
3
TBDMSCl Et3N(DMAP)
DMF
RT, overnight
High vacuum
4
TBDMSCl imidazole
DMF
RT, overnight
Filtration
5
TBDMSCl Et3N(DMAP)
DMF
RT, overnight
EtOAc extraction

Yield (%)
10
35
17
24
63-92

Firstly, DMF and DCM were used as the solvent system in the reaction according
to the reported procedure.[86] However, the reaction didn’t go to completion even
after 48 hours. Moreover, removal of DMF was troublesome. DMF is a widely used
polar solvent (polar index 6.4) with a boiling point of 155 oC, which explains the
difficulty for its removal. As shown in Table 3.2, Entry 1, DCM (polar index 3.1)
was firstly chosen to extract the product; however, a poor yield of only 10% of
product was obtained. Later, as shown in Table 3.2, Entry 2, DMF was used as the
only solvent to dissolve the starting cytidine. The reaction was complete after 12
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hours, which proved DMF is a good solvent for this reaction, and DMF was also
removed by extraction with DCM, offering a 35% yield of desired product. To
optimize conditions, different methods were tried to remove DMF after the reaction.
In Table 3.2, Entry 3, DMF was removed at 50 oC by rotary evaporator linking with a
high vacuum (<10 mbar). Unfortunately, the desired product was not stable under
these conditions, and decomposed to cytidine as evidenced by NMR and MS
examination. To find a simple and efficient procedure to remove DMF, the method
reported by Debarge et al.[84] was also tried (Table 3.2, Entry 5). In this approach,
the reaction mixture was stirred overnight at room temperature in the presence of
imidazole, and then poured into crushed ice/water, next, DMF was removed by
filtration. However, a low yield of only 24% of product was obtained compared with
the reported high yield (91%).
After four trials, it was realised that two factors play an essential role in this
reaction. One is solubility of the starting cytidine which contains three hydroxyl
groups and one amino group; the other issue is removal of DMF without decomposing
the desired compound. Based on the previous experience, EtOAc (polar index 4.4)
was used for the extraction to increase the yield due to the polarity of the desired
product (Table 3.2, Entry 4). Several attempts were tried using these conditions,
generating the desired compound in a range of 63-92% yield.
The structure of the desired compound 31 was confirmed though 1H NMR
spectroscopy, which revealed a singlet at 0.08 ppm with an integration of six protons,
ascribed to the two methyl groups attached to silicon [Si(CH3)2]. Silicon donates
electrons to protons, making the peak shift upfield. A singlet appeared at 0.88 ppm
with an integration of nine protons corresponding to the methyl protons in the tertbutyl group [C(CH3)3]. Moreover, two doublet of doublets appeared at 3.79 ppm and
3.92 ppm, respectively, with same coupling constants (geminal 2JH5’a-H5’b = 10.5 Hz,
vicinal 3JH5’a-H4’ = 3JH5’b-H4’ =4.5 Hz), and were ascribed to H5’a and H5’b. A multiplet
with an integration of three protons was observed at 4.14-4.27 ppm, corresponding to
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H2’, H3’ and H4’. A doublet (3JH1’-H2’ = 3.7 Hz) due to proton-proton coupling
appeared at 5.95 ppm, and was ascribed to H1’ attached to the electron withdrawing N
atom. Two doublets (3JH5-H6 = 7.5 Hz) due to vicinal coupling appeared at 5.85 ppm
and 8.01 ppm respectively, corresponding to H5 and H6. The 1H NMR spectral data
for this compound matched those reported in the literature.[86] The MS displayed a
base M + H+ peak at m/z= 358, corresponding to the expected formula of
C15H27N2O6Si.

3.1.2 Synthesis of N4–acetyl-1-(2’,3’-di-O-acetyl-5’-O-tert-butyldimethylsilyl-β D-arabinofuranosyl)cytosine (32)
Protection of the two secondary hydroxyl groups and the amino group was
achieved by standard peracetylation. The selectively protected silylated cytidine 31
was reacted with excess acetic anhydride in the presence of pyridine, generating the
desired product 32 in good to excellent yield according to the method of Rodríguez et
al. (see Scheme 2.13). The reaction was performed successfully more than 10 times to
generate sufficient material for the subsequent steps.

Reagents and conditions: (i) Ac2O (10 eq.), pyridine, 0 oC-RT, 16 h, 51-91%.
Scheme 3.2 Synthesis of silyl protected tri-N/O-acetylated cytidine 32.

Herein, the harmful solvent pyridine was used as both solvent and base. The high
boiling point (115 oC) of pyridine consequently led to difficulty during its removal
after reaction. This problem was overcome by adding a small amount toluene to the
reaction mixture, forming an azeotrope to decrease the overall boiling point for
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pyridine (110 oC). For removal of a large amount of pyridine, CuSO4 solution was
added into the concentrated mixture, forming a deep blue water-soluble complex with
pyridine, followed by the use of DCM to extract the compound. This was repeated
several times until disappearance of the blue colour.[90] The DCM layer was
collected and dried afterwards. The desired compound was further purified by column
chromatography, providing the desired compound 32 in good to excellent yield (5191%).
The structure of the compound, obtained as a white foam, was determined
through 1H NMR spectroscopy. Three singlets with an integration of three protons
each appeared at 2.06 ppm, 2.09 ppm and 2.27 ppm, and were ascribed to the methyl
protons in the acetyl groups. The methyl protons in the TBDMS group were firstly
identified from two singlets at 0.13 ppm and 0.93 ppm with an integration of six and
nine protons, respectively. Moreover, two doublet of doublets appeared at 3.82 ppm
and 3.98 ppm respectively with the same coupling constants (geminal 2JH5’a-H5’b =
10.5 Hz, vicinal 3JH5’a-H4’ = 3JH5’b-H4’ =4.5 Hz), were ascribed to H5’a and H5’b. A
quartet (3JH5’a-H4’ = 3JH5’b-H4’ = 3JH4’-H3’ = 4.5 Hz) due to vicinal coupling appeared at
4.27 ppm, corresponding to H4’, and a multiplet with an integration of two protons
was observed at 5.35-5.38 ppm, corresponding to H2’ and H3’. A doublet (3JH1’-H2’ =
4.5 Hz) was observed downfield at 6.35 ppm and was ascribed to H1’ attached to the
electron withdrawing N atom. Two doublets (3JH5-H6 = 7.5 Hz) due to vicinal coupling
appeared at 7.38 ppm and 8.31 ppm respectively, corresponding to H5 and H6 of the
pyrimidone ring. The 1H NMR spectral data for this compound matched those
reported in the literature.[86] In addition, a strong M + Na+ peak appeared at m/z= 506
in the ESI+ spectrum, corresponding to the formula C21H33N3NaO8Si, which also
confirmed the formation of 32.
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3.1.3 Synthesis
of
cytosine (18)

N4–acetyl-1-(2’,3’-di-O-acetyl-5’-β-D-arabinofuranosyl)

The selective deprotection of the TBDMS protecting group without affecting the
acetyl groups on 32 can be achieved through the use of specific desilylating reagents.
Tetrabutylammonium fluoride (TBAF) is the most widely used desilylating reagent
for the cleavage of silyl ether protecting groups.[91-93] The proposed mechanism of
TBAF deprotection of the silyl ether group of 32 is explained below. TBAF is a
source of fluoride anions which can attack the vacant d-orbital of silicon of the silyl
protected tri-N/O-acetylated cytidine 18, forming a pentavalent silicate, followed by
cleavage of the silyl ether protecting group due to the Si–F bond strength, which is
stronger than the Si–O bond (see Figure 3.3).[93-95]

Figure 3.3 The mechanism of TBAF deprotection of cytidine 32.

The method developed by Rodríguez et al. employed TBAF and acetic acid for
the selective deprotection of the TBDMS group on cytidine 32. Several attempts were
tried and the desired product 18 was obtained in yields of 59-76% (see Scheme 2.14).

51

Chapter 3 - Synthesis of the Protected Cytidine Fragment

Reagents and conditions: (i) Acetic acid (1.5 eq.), TBAF (3 eq.), anhydrous THF, 0 oC, 2 h, 59-76%.
Scheme 3.3 Synthesis of tri-N/O-acetylated cytidine 18.

The structure of the colourless solid obtained for the tri-N/O-acetylated cytidine
18 was confirmed though 1H NMR spectroscopy, which displayed three singlets with
an integration of three protons each, at 2.07 ppm, 2.11 ppm and 2.27 ppm, ascribed to
the methyl protons in the three acetyl groups. Two doublet of doublets appeared at
3.84 ppm and 4.00 ppm respectively with same coupling constants (geminal 2JH5’a-H5’b
= 10.5 Hz, vicinal 3JH5’a-H4’ = 3JH5’b-H4’ =4.5 Hz), were ascribed to H5’a and H5’b. A
quartet (3JH5’a-H4’ = 3JH5’b-H4’ = 3JH4’-H3’ = 4.5 Hz) due to vicinal coupling appeared at
4.26 ppm, corresponding to H4’, and two triplets (3JH4’-H3’ = 3JH3’’-H2’ = 3JH2’-H1’ =
4.5Hz) with an integration of one proton each were observed at 5.50 and 5.59 ppm,
corresponding to H3’ and H2’. A doublet (3JH1’-H2’ = 4.5 Hz) was observed downfield
at 6.03 ppm and was ascribed to H1’ attached to the electron withdrawing N atom.
Two doublets (3JH5-H6 = 7.5 Hz) due to vicinal coupling appeared at 7.47 ppm and 8.26
ppm respectively, corresponding to H5 and H6 of the pyrimidone ring. Both the 1H
NMR spectral data and physical data matched those reported in the literature.[86] In
addition, the structure was further proven by a strong M + Na+ peak which appeared
at m/z = 392, corresponding to the expected formula of C15H19N3NaO8.
So far, a large scale (overall more than 10 g) of tri-N/O-acetylated cytidine 18
was prepared, as a key protected cytidine bearing a free 5’-OH for coupling with αhydroxyphosphonate derivatives. However, this is a three-step approach with an
overall yield of 64% from cytidine. Moreover, it usually took 3-4 days to obtain the
desired tri-N/O-acetylated cytidine from the commercially available cytidine
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including two overnight reactions, removal of troublesome solvents (DMF and
pyridine) and three column chromatography purification steps. Furthermore, it is a
high cost approach due to the solvent and column usage.
Fortunately, protection of the 2’- and 3’-hydroxyl groups of cytidine with an
isopropylidene group offered us a new idea for the protected cytidine synthesis. The
2’, 3’-isopropylidincytidine can also achieved by acetonide protection of the 2’, 3’diol of cytidine. This protection reaction usually takes several hours and generates the
desired product in high yield (83-97%).[96-98] Therefore, this cheap, concise and
one-step approach was tried to prepare 2’, 3’-isopropylidincytidine (33) in order to
optimise our methodology.

3.2 Synthesis of 2’, 3’-isopropylidene-cytidine (33)
Isopropylidene protected nucleosides are widely reported for oligonucleotide
analogue preparation. Purohit et al. demonstrated an alternative pathway for the
introduction of the CMP moiety, starting with an isopropylidene-protected cytidine
and reacting with diethyl chlorophosphate in the presence of pyridine, generating
conjugate (34) (see Figure 3.4 (a)).[97] Recently, Kumar et.al reported a new class of
sialyltransferase inhibitor (35) linking the sialic residue and CMP moiety with a
nonionic triazole, which was prepared from N-acetyl-2’,3’-di-O-isopropylidene
cytidine (see Figure 3.4 (b)).[99] More details of this reaction will be presented in
Chapter 4, Part B. In 2010, Quintero et al. developed an isopropylidene protected
thymine as a key precursor, which was reacted with phosphoryl chloride and 5-aryl-αD-xylofuranose

derivatives, generating a series of cyclic nucleotide analogues (e.g.

36) (see Figure 3.4 (c)).[100] Moreover, 2’, 3’-isopropylidineuridine was used by
Thirumalairajan’s group to prepare orotidine 5’-monophosphate (OMP) analogues
(37) (see Figure 3.4 (d)).[96] Xu et al. reported the preparation of a new class of
neamine-cytidine conjugates (e.g. 38) by coupling isopropylidene protected cytidine
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with neamine utilising ethylenediamine-amino acid as a linker (see Figure 3.4
(e)).[101]

Figure 3.4 Reported applications of isopropylidene-protected nucleosides.

Isopropylidene protected nucleosides have been shown to be quite stable and
have been widely used for coupling the 5’-hydroxyl group of nucleosides without
affecting the amino group of the base in the nucleoside (see Figure 3.5).[96, 97, 100,
101] In addition, the isopropylidene protecting group can also be easily removed by
adding 1M hydrochloric acid after the coupling reaction.[98] Hence, it was decided to
prepare a small amount of 2’,3’-isopropylidincytidine (33) from cytidine for
methodology optimisation. Acetone and dimethoxypropane are the two most widely
used reagents for syn diol protection in the presence of catalytic acid, and the
proposed mechanism of this reaction is shown below (see Figure 3.5). The protonated
dimethoxypropane reacts across the 1,2-diol to give a five-membered ring, generating
the protected 2’, 3’-isopropylidincytidine (33) and leaving the 5-OH group free.[102]
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Figure 3.5 Proposed mechanism of acetonide protection.

Catalytic acids play an essential role in this reaction according to the mechanism.
Several attempts were tried to protect the 2’- and 3’-hydroxyl groups of cytidine as an
acetonide. The method discovered by Thirumalairajan et al. [96] to prepare
isopropylidene protected uridine was firstly adapted and repeated within the current
work. The suspension of cytidine, dimethoxypropane and catalytic p-toluenesulfonic
acid (TsOH) in acetone was heated to gentle reflux for one hour. However, there was
still a large amount of starting cytidine remaining after 12 hours. Then, the solution
was neutralised and no desired product was purified by flash chromatography (see
Table 3.3, Entry 1), which suggested p-toluenesulfonic acid (TsOH) is not an
efficient catalyst in this reaction. In 2012 Purohit et al. reported the successful
preparation of acetal protected cytidine in 97% yield by employing concentrated
sulphuric acid (conc. H2SO4) as the catalytic acid and anhydrous acetone as both
solvent and acetal reagent.[97] A trial based on this approach was tried (see Table 3.3,
Entry 2), however, there was still a large amount of starting material remaining and
the generation of a few compounds which were not desirable. In these two trials,
cytidine was prepared as a suspension due to its poor solubility. There was a large
amount of starting cytidine remained even after strong conditions (reflux, 12 hour),
which suggested that acetone did not offer a good phase for strong acid (TsOH and
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conc. H2SO4) to protonate the acetone and dimethoxypropane, so as to catalyse the
whole reaction consequently.
In the synthetic approach developed by Lusic et al., 70% perchloric acid (HClO4)
was added dropwise into a solution of cytidine and dimethoxypropane in acetone until
the solution turned clear, to make sure the acid protonated the acetone and
dimethoxypropane.[101] This method was used in Table 3.3, Entry 3 and the mixture
was stirred for two hours then neutralised, concentrated and purified by silica gel
chromatography, offering the desired 2’, 3’-isopropylidene-cytidine in 78% yield.
Table 3.3 Conditions trialled for synthesis of the 2’,3’-O-isopropylidenecytidine (33).

Entry

Acetal Reagent

Acid

Solvent

Conditions

Yield (%)

1

2,2-Dimethoxypropane

TsOH·H2O

Anh. acetone

Reflux, 12 hours

0

2

Acetone

Conc. H2SO4

Anh. acetone

RT, 12 hours

0

3

2,2-Dimethoxypropane

70% HClO4

Anh. acetone

RT, 2 hours

78

The structure of the compound, which was obtained as a white solid, was
determined through 1H NMR spectroscopy. Two singlets with an integration of three
protons each appeared at 1.33 ppm and 1.53 ppm respectively, which were ascribed to
the six methyl protons of the isopropylidene group. Two doublet of doublets appeared
at 3.68 ppm and 3.75 ppm respectively with the same coupling constants (geminal
2

JH5’a-H5’b = 12.0 Hz, vicinal 3JH5’a-H4’ = 3JH5’b-H4’ =4.0 Hz) and were ascribed to H5’a

and H5’b. A quartet (3JH5’a-H4’ = 3JH5’b-H4’ = 3JH4’-H3’ = 4.0 Hz) due to vicinal coupling
appeared at 4.27 ppm, corresponding to H4’, and a multiplet with an integration of
two protons was observed at 4.84-4.87 ppm, corresponding to H2’ and H3’. A doublet
(3JH1’-H2’ = 2.5 Hz) was observed downfield at 5.78 ppm and was ascribed to H1’
attached to the electron withdrawing N atom. Two doublets (3JH5-H6 = 7.5 Hz) due to
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vicinal coupling appeared at 5.88 ppm and 7.80 ppm respectively, corresponding to
H5 and H6. All of the 1H NMR spectral data matched those reported in the
literature.[98] A strong M + Na+ peak appeared at m/z= 306 in the ESI+ spectrum,
corresponding to the formula C12H17N3O5Na, which also confirmed the formation of
33.

3.3 Summary
In conclusion, this chapter reported the successful synthesis of the suitably
protected cytidine precursor, the tri-N/O-acetylated cytidine (18) and 2’, 3’-Oisopropylidene-cytidine (33), via two different approaches. A large scale (overall more
than 10 g) of tri-N/O-acetylated cytidine (18) was prepared as a key precursor for
coupling with the α-hydroxyphosphonate derivatives prepared in Chapter 2. Details of
these coupling will be described in the next chapter. Within the three classical steps
preparation from commercially available cytidine, two intermediate products, silyl
protected cytidine (31) and silyl protected tri-N/O-acetylated cytidine (32), were fully
characterised and their reaction conditions were modified to obtain excellent yields
(>90%).
In addition, simultaneous protection of the 2’- and 3’-hydroxyl groups of cytidine
with an isopropylidene group offered us a new idea for protecting the cytidine moiety.
The 2’, 3’-O-isopropylidene-cytidine (33) was successfully prepared in good yield
(78%) by acetonide protection of the 2’, 3’-diol of cytidine, which reduced the
original high cost and multi-step preparation to a new, cheaper and more concise onestep method. This will be the first use of an acetonide protected cytidine in
sialyltransferase inhibitor synthesis, and will significantly decrease time and cost, and
simplify the complex steps involved in the preparation of novel sialyltransferase
inhibitors.
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4 CHAPTER 4
Part A
Synthesis of Sialyltransferase Transition-State Analogue
Inhibitors via Phosphoramidite Approach
4.1 Phosphoramidite

approach

for

sialyltransferase

inhibitor

synthesis
The phosphoramidite coupling method, which employs a phosphordiamidite such
as (19) to link two hydroxyl containing compounds via a phosphite bond, is widely
used in organic chemistry (see Figure 4.1). This method is applied in the preparation
of various phosphorylated biomolecules, such as nucleoside carbohydrate conjugates
[103], phospholipids [104] and glycopeptides.[105] In particular, it is highly effective
for automated solid-phase DNA/RNA oligonucleotide synthesis.[106-108]

Figure 4.1 General scheme for a phosphoramidite coupling of two alcohols via a phosphite link.

This approach is also largely used for sialyltransferase inhibitor preparation. In
1995, Kajihara et al. firstly reported the efficient chemical synthesis of the natural
sialyltransferase donor, cytidine-5’-monophospho-N-acetylneuraminic acid (8) (CMPNeu5Ac),

via

coupling

2-cyanoethyl-2’,3’-O,N4-tri-acetylcytidin-5’-yl-N,N-

diisopropylphosphoramidite (21) (5’-amidite) with pentaacetyl Neu5Ac via the
phosphoramidite approach.[109] One year later, several CMP-NeuAc derivatives
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were generated by Chappell et al. from tri-N/O-acetylated cytidine according to the
same approach utilising allyl-N,N,N’,N’-tetraisopropylphosphordiamidite as the
phosphorylation reagent.[110] Meanwhile, Cohen et al. reported the synthesis of an
anomeric sulphur analogue of CMP-NeuAc by coupling tri-N/O-benzoyl cytidine-5phosphoramidite with a glycosyl thiol of a protected sialic acid in the presence of
tetrazole.[111] Later, this approach was employed by Schmidt’s group to prepare
novel sialyltransferase transition-state analogue inhibitors via a 5’-amidite (21).[19,
20, 50, 52, 53] In this chapter, we give a detailed description of our attempts to
synthesise a novel series of sialyltransferase transition-state analogue inhibitors 15a-i
via the phosphoramidite approach (see Figure 4.2). Tri-N/O-acetylated cytidine (18) is
reacted with phosphordiamidite (19) in the presence of a tetrazole activator (20), to
generate the key 5’-amidite (21) intermediate. Next, the 5’-amidite (21) is reacted
with the α-hydroxyphosphonate derivatives 16a-i or 17a-i, followed by oxidation and
hydrolysis to generate the desired sialyltransferase transition-state analogue inhibitors
15a-i.
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Figure 4.2 General pathway for sialyltransferase inhibitor synthesis via the phosphoramidite approach.

4.2 Synthesis of 2-cyanoethyl-2’,3’-O,N4-tri-acetylcytidin-5’–yl -N,Ndiisopropylphosphoramidite (21)
4.2.1 Reported synthesis method
Synthesis

of

2-cyanoethyl-2’,3’-O,N4-tri-acetylcytidin-5’-yl-N,N-diisopropyl

phosphoramidite (21) from tri-N/O-acetylated cytidine (18) and a phosphorylation
reagent in the presence of an activator is the key and most challenging step in the
preparation of sialyltransferase inhibitor. According to the method developed by
Kajihara et al., the tri-N/O-acetylated cytidine (18) can be reacted with the
phosphorylation

reagent

2-cyanoethyl-N,N,N’,N’-tetraisopropylphosphordiamidite

(19) using diisopropylamine as a base in the presence of 1H-tetrazole (20) in a MeCN
and DMF solvent system, to generate the key 5’-amidite (21) intermediate in 72%
yield (see Scheme 4.1).

Reagents and conditions: (i) 2-Cyanoethyl-N,N,N’,N’-tetraisopropylphosphorodiamidite (2 eq.),
diisopropylamine (2 eq.), tetrazole (2 eq.), MeCN, DMF, room temperature, 1 h, 72%.
Scheme 4.1 Reported synthesis of protected phosphoramidite (21).[109]

However, this reaction is not easy to reproduce for several reasons. Firstly, it is a
highly moisture-sensitive reaction, therefore no water can be introduced during the
whole reaction process, necessitating the use of oven dried flasks, anhydrous solvents
and a nitrogen or argon atmosphere. Secondly, this reaction is hard to optimise due to
its multi-parameters, including four reagents and one solvent system. Thirdly, the
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desired 5’-amidite (21) is not stable and usually oxidises to phosphate or decomposes
after standing for hours. Lastly and most importantly, 1H-tetrazole (20), which is the
most widely used and most efficient activator, is not available to be shipped to
Australia due to its explosive nature. Furthermore, the tetrazole alternatives that are
commercially available here are far less reactive in this reaction, as will be explained
in more details below.

4.2.2 Phosphorylation reagents
2-Cyanoethyl N,N,N’,N’-tetraisopropylphosphordiamidite 19 (referred to here as
the bis-amidite reagent) is a widely used phosphorylating reagent.[112] It has shown
great utility in coupling with nucleobases or carbohydrates via their phosphotriesters
in moderate yields under mild reaction conditions.[103-108] Phosphordiamidite (19)
was used by Sheppard et al. in preparing carbohydrate phosphoramidites as
nucleoglycoconjugate building blocks in good yields in the presence of
diisopropylammonium

tetrazolide

under

anhydrous

conditions.

Then,

the

monosaccharide phosphoramidite was coupled with DNA oligonucleotides by solidphase chemistry.[113] Recently, Yamada’s group used phosphorodiamidite (19) to
synthesize uridine 3’-phosphoramidite building blocks in good yield with
diisopropylammonium tetrazolide as a catalyst under anhydrous conditions, for
developing oligonucleotides containing new 2’-O-modified ribonucleosides as nucleic
acid drugs.[114] Moreover, this reagent was also used to prepare glycoconjugate
polymers which carry bioactive analogues of main cell membrane glycolipids of
Mycoplasma fermentas, by Nishida and co-workers in an overall yield of 54%.[115]
In 2000, Lin and colleagues reported a simple and efficient pathway to prepare boroncontaining

ADP

analogues

from

2’,3’-di-O-acetyladenosine

by

using

phosphorodiamidite (19) as the phosphorylating reagent, in the presence of
diisopropylammonium tetrazolide (in 36% overall yield).[116] Additionally,
comparing with 2-cyanoethyl-N,N-diisopropyl chlorophosphoramidite (40) (another
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commonly used phosphorylating reagent), which is expensive but very reactive,
phosphorodiamidite (19) is cheaper and more stable towards hydrolysis and oxidation
(see Figure 4.3). However, it is less reactive and requires the use of activators such as
1H-tetrazole.[117, 118] Based on cost and stability, phosphordiamidite (19) was
selected as the phosphorylating reagent for our 5’-amidite preparation.

Figure 4.3 Structures of the two most common phosphorylation reagents.

4.2.3 1H-Tetrazole and alternatives
1H-Tetrazole (20) is a four-nitrogen heterocycle that is widely used in organic
synthesis but has been reported to be toxic and explosive upon heating or heavy
impact. 1H-Tetrazole is the most efficient activator in oligonucleotide analogue
synthesis. The proposed mechanism of how tetrazole activates phosphorodiamidite
(19), and catalyses the formation of 5’-amidite (21) is shown below (see Figure
4.4). 1H-Tetrazole (pKa 4.89) has dual roles in this reaction. Firstly, it protonates the
bis-amidite reagent (19) as an acid; secondly, the conjugate base of tetrazole works as
a nucleophile to undergo nucleophilic attack on the N,N-diisopropylamino group,
generating a very reactive tetrazolide intermediate by a slower step. The tetrazolide
intermediate reacts quickly with the free 5’-OH of tri-N/O-acetylated cytidine (18) to
yield the 5’-amidite (21).[117-119]
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Figure 4.4 Mechanism of formation of 5’-amidite (21) in the presence of 1H-tetrazole.

Due to tetrazole’s explosive nature, however, it is not available in Australia.
Therefore, finding a good alternative activator instead of 1H-tetrazole (19) turned out
to be crucial for the synthesis of the key intermediate (21) or even the whole project.
Several alternatives, such as 5-ethylthio-1H-tetrazole (41) (SET),[98, 106] 5benzylthio-1H-tetrazole (42) (BTT),[105, 120-122] and dicyanoimidazole (43)
(DCI),[123] were reported to be efficient for oligonucleotide synthesis in the literature
(see Figure 4.5).

Figure 4.5 Structure of 1H-tetrazole and its alternatives.
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Dicyanoimidazole (43) (DCI) was firstly considered due to its greater safety. In
comparison with 1H-tetrazole, DCI also has four nitrogens, but it is not an explosive
compound. In a study comparing different phosphorylation activators by Sanhvi’s
group, 1H-tetrazole offered an excellent yield (94%) of the nucleoside
phosphoramidite (see Table 4.1, Entry 1).[118] While DCI was reported by Vargeese
et al. as a good substitute for 1H-tetrazole (20), offering an efficient activation of
protected

deoxythymidine

phosphoramidite

and

generating

the

desired

phosphoramidite in good yield (75%) in three hours under an argon atmosphere (see
Table 4.1, Entry 2).[123] However, it should be noted that this activator gave a lower
yield when using acetonitrile (see Table 4.1, Entry 3).[118]
There are another two 1H-tetrazole alternatives that are often used for activating
phosphorylation reagents. 5-Ethylthio-1H-tetrazole (41) (SET) and 5-ethylthio-1Htetrazole (42) (BTT) are widely used in standard solid phase oligonucleotide synthesis
to prepare modified DNA or RNA derivatives. Recently, Hentschel et al. reported the
successful preparation of modified deoxyguanosine phosphoramidite in good yield
(80%) employing SET as an activator for coupling with the 5’-hydroxl group in
another nucleoside (see Table 4.1, Entry 4).[106] SET was also used by Lusic’s
group as an activator to catalyse the synthesis of modified 5-formylcytidine
phosphoramidite in short RNA analogue preparation, providing an excellent yield of
93% (see Table 4.1, Entry 5).[98] In 2009, Hassan et al. developed an efficient
pathway to prepare 5-Se-thymidine DNAs through solid phase synthesis employing
phosphoramidite building blocks, in which the key intermediate phosphoramidite was
prepared in a good yield (82%) by reaction with the bis-amidite reagent in MeCN and
BTT as the activator in the presence of base (see Table 4.1, Entry 6).[124]
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Table 4.1 Comparison of reported oligonucleotides synthesis employing tetrazole and alternatives as
activators.

Entry
1
2
3
4
5
6

Activator
Tetrazole
DCI
DCI
SET
SET
BTT

PKa
4.89
5.20
5.20
4.28
4.28
4.08

Solvent
DCM
DCM
MeCN
DCM
DCM
DCM

Time
3h
3h
2h
20 min
16 h
2h

Yield (%)
94
75
51
80
93
82

Based on the 1H-tetrazole activation mechanism described earlier (see Figure
4.4), the acidity of the activator and the nucleophilicity of its conjugate base are the
two major factors for consideration. 1H-Tetrazole is acidic (pKa 4.89), which is the
reason for protonation of the bis-amidite reagent, and then catalyses the reaction.[118]
The acidity of DCI (pKa = 5.20) < 1H-Tetrazole (pKa 4.89) < SET (pKa 4.28) < BTT
(pKa 4.08), which will effect protonation. Furthermore, the sizes of activators such as
DCI, SET and BTT compared with 1H-tetrazole were also considered in terms of
steric hindrance during the activation step. Based on this, SET was chosen after
comparison to be the preferred alternative due to its greater acidity and as it is less
sterically encumbered than the other examples.

4.2.4 Synthesis
of
2-cyanoethyl-2’,3’-O,N4-tri-acetylcytidin-5’-yl-N,Ndiisopropylphosphoramidite
4.2.4.1 Attempted preparation of 5’-amidite (21)
A number of attempts were tried to prepare the 5’-amidite (21) according to
Kajihara’s method employing SET as the alternative activator. All of the reactions
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were performed under an inert atmosphere using a Schlenk line and monitored by
TLC. The extent of reaction was checked after both 2 and 24 hours (see Table 4.2).

Table 4.2 Conditions trialled for the preparation of 2-cyanoethyl-2’,3’-O,N4-tri-acetylcytidin -5’-ylN,N-diisopropyl phosphoramidite (21).

Entry

Scale (mg)

1
100
2
100
3
100
4
120
5
70
6
200
7
200
8
200
*contain by-product

Base

Solvent

HN(iPr)2
HN(iPr)2
HN(iPr)2
HN(iPr)2
HN(iPr)2
HN(iPr)2
HN(iPr)2

MeCN, DMF
DCM
MeCN
THF, DMF
DCM, DMF
THF, DMF
THF, DMF
THF, DMF

Mol ratio
18 : SET: 19
1: 2: 2
1: 2: 2
1: 2: 2
1: 2: 2
1: 2: 2
1: 1.2: 1.2
1: 1.2: 1.2
1: 1.5: 1.5

Time (h)

Yield (%)

2, 24
2, 24
2, 24
2, 24
2, 24
2, 24
2, 24
2, 24

30*
0
0
45*
20*
0
0
0

Initially, the phosphoramidite reaction was performed according to the procedure
described by Kajihara et al. except using SET in place of 1H-tetrazole (see Table 4.2,
Entry 1). One equivalent of the triacetylated cytidine (18) was reacted with two
equivalents of SET and the bis-amidite reagent (19) in MeCN and DMF (5 : 1) using
diisopropylamine as a base. However, this reaction didn’t go to completion even after
24 hours, compared to the literature reaction with tetrazole which took only one hour.
The reaction mixture was diluted with EtOAc and washed with NaHCO3 to remove
excess SET, and the EtOAc layer was collected after extraction, followed by
purification by column chromatography (MeOH/EtOAc = 1: 19 with 5% TEA). The
desired product fractions were collected and concentrated to give a yellow oil in 35%
yield. However, it was identified to be a mixture of the desired product (21) and an
unknown impurity upon examination of the NMR spectrum.
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Evaluation of the mass spectrum of the product mixture revealed a strong M +
Na+ peak at m/z 592, corresponding to the expected formula for (21) of
C24H36N5NaO9P. The structure of the 5’-amidite (21) was confirmed though 1H NMR
spectroscopy. For example, two doublets (J = 7.5 Hz) due to chiral phosphate with an
overall integration of one proton appeared at 8.23 ppm and 8.24 ppm, and were
ascribed to H6. Similarly, H5 was identified from a doublet of doublets (J = 7.5 Hz)
with an overall integration of one proton, which appeared at 7.41ppm and 7.43 ppm.
H1’ was identified from two doublets (J = 5.5 Hz) with an overall integration of one
proton at 6.30 ppm. Four singlets appeared at 2.05, 2.06, 2.09 and 2.10 ppm with an
overall integration of six protons, corresponding to methyl protons in acetyl groups
attached to oxygen atoms. The acetyl group attached to the amine was observed as a
singlet at 2.24 ppm. All of above peaks and coupling patterns confirmed the presence
of diastereomers due to the chiral phosphite and matched the data reported in the
literature.[109, 111]
However, there were also by-product signals that appeared in the 1H NMR
spectrum. Two singlets with an integration of half a proton each appeared at 7.58 ppm
and 6.34 ppm respectively. Moreover, the multiplets that appeared at 3.46-4.25 ppm
showed more than the expected six protons for the 5’-amidite (2× CH(CH3)2 + H5’a,
H5’b+ H1’’a, H1’’b), and the multiplets appearing at 2.62-2.70 ppm also showed an
integration of more than the expected two protons (H2’’a, H2’’b). Furthermore, the
multiplets that appeared at 1.24-1.27 ppm showed an integration of more than
expected 12 protons for the two isopropyl groups (see Figure 4.6). In the

13

C NMR

spectrum, four secondary carbons were observed, which is in contrast to the two
secondary carbons in the 5’-amidite structure. All of above results suggested that there
was an unknown compound mixed in with the desired 5’-amidite after column
chromatography. The unknown impurity was firstly thought to be excess Et3N from
column chromatography or unreacted bis-amidite reagent as the reaction didn’t go to
completion.
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Figure 4.6 1H NMR spectrum and MS of desired 5’-amidite (19) and the unknown compound.

In 2000, Sanghvi et al. pointed out that finding a highly soluble solvent for both
the protected nucleoside and activator is one of the biggest challenges for the
phosphitylation reaction.[118] Hence, different solvent systems were firstly tried to
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make the reaction go to completion (see Table 4.2, Entry 2-5). What was observed is
that, firstly, DCM was not polar enough to dissolve the tri-N/O-acetylated cytidine
(18), and no desired product formed. Though MeCN can dissolve the tri-N/Oacetylated cytidine (18), none of these three solvents can dissolve the tetrazole
diisopropylammonium salt (which is formed by SET and diisopropylamine). So the
reaction didn’t work as well. Next, THF/DMF and DCM/DMF solvent mixtures were
used to dissolve the tetrazole diisopropylammonium salt (see Table 4.2, Entry 4 and
5), and generated a mixture of the desired product 5’-amidite (21) in 20-45% yield,
along with the unknown compound, which confirmed that solubility of solvent is one
of the key issues in this kind of reaction, as reported in the literature.
To further understand what was happening, some model reactions were
performed that will be described in the next section. In addition, using ninhydrin as a
stain in these reactions led to a breakthrough in identifying the unknown compound.
Ninhydrin is employed for detecting amines on a TLC that are otherwise UV inactive.
When the reaction mixture form one of the successful phosphitylation attempts (Table
4.2, Entry 4), was spotted on a TLC plate, the desired product and unreacted
triacetylated cytidine were observed, but not the bis-amidite reagent, which is not UV
active (see Figure 4.7, left TLC). After treating the same plate with ninhydrin, several
by-products, which contain an amine group were observed. One of these by-products
formed from the bis-amidite reagent (19) had a similar Rf value as the desired 5’amidite (21) even in a polar solvent system (MeOH/EtOAc = 1: 19), which led to the
difficulty in isolating pure 5’-amidite (see Figure 4.7, right TLC). A number of
solvent systems were tried for the purification of the 5’-amidite (21), but none of them
provided a good separation factor between the desired product and the by-product.
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Legend
1= starting material
(triacetylated cytidine)
2= activator (SET)
3= bis-amidite reagent
4= crude product

Figure 4.7 TLC spectrum (silica, MeOH: EtOAc= 1:19) of crude product for the phosphoramidite
reaction (Table 4.2, Entry 4).

Since the unknown compound, which resulted from excess or unreacted bisreagent (19), was not easy to isolate from the desired 5’-amidite (21), it was
favourable to use less bis-reagent (19) for subsequent trials. Sanghvi et al. pointed out
that the ratio of nucleoside: activator: bis-reagent of 1: 1.2: 1.2 is the most desirable
for this kind of reaction, which could also be performed without any base and gave
excellent yields.[118] Therefore, it was decided to utilise this lower ratio of reagents
minimising the excess bis-reagent usage (see Table 4.2, Entry 6 and Entry 7). No
base was added in Entry 6 to check the effect of base. However, none of these two
trials worked after 1H NMR and MS examination. The ratio of nucleoside: activator:
bis-reagent was increased to 1: 1.5: 1.5 as shown in Entry 8, but unfortunately, there
was no desired compound formed either. Although we were unable to optimise the
reaction and increase the yield of desired product beyond 45%, of the eight different
reaction conditions trialled, three of them (Table 4.2, Entries 1, 4 and 5) were
successful in producing the desired 5’-amidite (21), albeit contaminated with a byproduct.
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4.2.4.2 Isolation and characterisation of the unknown compound
The by-product from the above reaction was eventually identified to be
compound (45). The unreacted or excess bis-amidite reagent (19) reacted with a
hydroxyl group from water during the extraction or from silica column
chromatography, generating the intermediate phosphite (44), followed by oxidation
from phosphite to the more stable phosphate (see Figure 4.8).

Figure 4.8 Formation of by-product (45) from unreacted or excess bis-amidite reagent (19).

The structure of the hydrolysis by-product was determined through 1H NMR
spectroscopy. A doublet with a large coupling constant of 625.0 Hz appeared at 6.9
ppm (thought as two singlets previously), and was ascribed to the proton attached to
the phosphate group (HPO). Two triplets (3JH1-H2 = 6.0 Hz) appeared at 4.07 ppm and
4.16 ppm with an integration of one proton each were ascribed to the two methylene
protons next to the cyano group. The other two methylene protons close to the oxygen
were observed from the two triplets (3JH1-H2 = 6.0 Hz) that appeared at 2.71 ppm and
2.73 ppm respectively. Two septets (3JH-H = 7.0 Hz) appeared at 3.46 ppm and 3.49
ppm were ascribed to the two methine protons in the isopropyl groups. The methyl
protons in the isopropyl groups were observed as two doublets with an integration of
six protons each that appeared at 1.21 and 1.22 ppm. In addition, a strong M+ H+ peak
at m/z= 219 in the ESI+ spectrum, corresponding to the formula C9H20N2O2P, further
confirmed the structure (see Figure 4.9).
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Figure 4.9 1H NMR spectrum and MS of by-product (45)

After comparison with the 1H NMR spectrum and MS of the mixture of the 5’amidite (21) and the impurity shown in Figure 4.5, the by-product peak at m/z= 241
(M+ Na+) was also found in the mixture’s ESI+ spectrum. Moreover, all the 1H NMR
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peaks of the by-product (45) matched with those excess peaks in the mixture’s 1H
NMR spectrum, which further confirmed the formation of by-product (45) in those
reactions.

4.2.5 Model reaction
Considering the cost and time spent on the three step preparation of the tri-N/Oacetylated cytidine (18), it was decided to set up a few trial model reactions for
condition optimisation for the phosphorylation step. 3,4-Dimethoxybenzyl alcohol
(46) was chosen due to its readily availability and structural similarity to mimic the
tri-N/O-acetylated cytidine (18). Moreover, the desired compound would be easy to
identify from the 1H NMR spectrum with methoxy protons around 3.9 ppm, along
with aromatic protons. All of these model reactions were performed based on the
method developed by Kajihara et al. (see Table 4.3).

Table 4.3 Conditions trialled for synthesis of the 2-cyanoethyl 3,4-dimethoxybenzyldiisopropyl
phosphoramidite (47).

Entry
1
2

Scale
(mg)
50
50

Activator

Base

Solvent

SET
SET

diisopropylamine
diisopropylamine

MeCN, DMF
MeCN, DMF

Mol ratio
46: act: 19
1: 1.2: 1.2
1: 1.5: 1.5

Time
(h)
12
12

Yield (%)
0
31*

*stands for by-product

Herein, two trials were chosen to be presented: 3,4-dimethoxybenzyl alcohol (46)
was reacted with the bis-amidite reagent (19) in the presence of SET as the activator
in a mixture of MeCN and DMF (5 : 1) using diisopropylamine as a base. The ratio of
nucleoside: activator: bis-reagent was decreased to 1: 1.2: 1.2 to avoid forming the
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by-product (45). However, analysis by TLC and 1H NMR spectroscopy revealed the
crude product contained the starting material 46 and no desired product (see Table
4.3, Entry 1). When the ratio of nucleoside: activator: bis-reagent was increased to 1:
1.5: 1.5 in Table 4.3, Entry 2, a coupled by-product, compound (48), was obtained in
31% yield instead of formation of the desired product (47). The formation of byproduct (48) suggests that the activator SET successfully activated the reaction.
Initially, SET protonates the bis-amidite reagent (19), followed by nucleophilic attack
on the diisopropylamino group by its conjugate base, to remove the diisopropylamino
group, generating the expected product (47). However, the tetrazole conjugate base is
very reactive, and removes another diisopropylamino group, generating the doubly
coupled by-product (48) (see Figure 4.10).

Figure 4.10 Formation of the doubly coupled by-product (48) from bis-amidite (19) and 3,4dimethoxybenzyl alcohol (46).

The structure of compound (48) obtained as a yellow oil, was confirmed from the
1

H NMR spectrum. Two triplets (3JH1’’-H2’’ = 7.0 Hz) appeared at 3.94 ppm and 3.95

ppm with an integration of one proton each were ascribed to the geminal methylene
protons next to the cyano group. The other two methylene protons close to the oxygen
were observed from two triplets (3JH1’’-H2’’ = 7.0 Hz) that appeared at 2.54 ppm and
2.55 ppm respectively. Two singlets at 3.85 ppm and 3.86 ppm with an integration of
six protons each, were ascribed to the methoxy protons, while two singlets at 4.81
ppm and 4.83 ppm with an integration of two protons each, corresponded to the four
methylene protons (H7, H7’) of the benzyl groups. The aromatic protons appeared at
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6.8-6.9 ppm with an integration of six protons. In addition, a strong M + Na+ peak
appeared at m/z= 458 in the ESI+ spectrum, corresponding to the formula C21H26
NaNO7P, further confirmed the structure. Even though the desired product was not
obtained, a thorough understanding of phosphoramidite reaction conditions was
acquired after a few model reactions.

4.3 Attempted synthesis of triethylammonium(2’,3’-O,N4-tri-acetyl
cytidin-5’-yl-)-(1-dibenzylphosphonato-2-phenylethyl)phosphate (49).

Reagents and conditions: (i) SET (2 eq.), DCM, room temperature, 3 h; (ii) t-BuOOH (1.5 eq.), room
temperature, 2 hours; (iii) Et3N (50 eq.), room temperature, 18 h.
Scheme 4.2 One-pot synthesis of triethylammonium phosphate (49) by coupling 5’-amidite (21) and
dibenzyl α-hydroxyphosphonate 17a.

Herein, the 5’-amidite (21) contaminated with a small amount of by-product (45)
was coupled with dibenzyl α-hydroxyphosphonate 17a directly according to
Skropeta’s one-pot synthetic approach with the SET activator instead of as reported
with 1H-tetrazole.[20] It should be noted that the 5’-amidite (21) is highly unstable
and can readily oxidise to the phosphate. The 5’-amidite (21) and dibenzyl αhydroxyphosphonate 17a (1 eq.) were evaporated and dried under vacuum. The
remaining foam was dissolved in dry CH2Cl2, and SET (2 eq.) was added whilst
stirring. All the 5’-amidite (21) was consumed after three hours as monitored by TLC.
Next, 1.5 equivalents of t-BuOOH (5.0- 6.0 M in decane) were added to oxidise the
phosphite to a phosphate, and after an additional hour, 50 equivalents of Et3N were
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added and the reaction stirred for a further 18 hours.
The crude reaction mixture was then concentrated and the residue was subjected
to column chromatography, but no pure products were obtained. TLC and MS
examination showed many impurities, which might result from the introduction of
H2O when the t-BuOOH (5.0- 6.0 M in decane) was added. The phosphite
intermediate is usually unstable, and can also lead to undesired decomposition.
Another reason for the impurities may be the reaction of the by-product (45). Based
on this trial, it was observed that, no water should be introduced during the whole
reaction. Moreover, the key 5’-amidite intermediate (21) should be fully characterised
before performing the second coupling step to avoid forming undesired products,
which further hamper the purification process.

4.4 Summary of Part A
In conclusion, part A of chapter 4 describes the modification of the key 5’-amidite
(21) intermediate preparation, utilising SET as an alternative tetrazole activator. After
several different trials, the 5’-amidite (21) was successfully prepared under the
modified conditions, which is the first example in sialyltransferase inhibitor synthesis
of preparing this key fragment using an activator other than tetrazole.
In addition, model reactions were performed to try to optimise the
phosphoramidite reaction conditions. The by-product obtained (48) in the model
reactions was characterised. Moreover, analysis of the factors that led to a low yield
of the 5’-amidite (21) and formation of the by-product (48) were explained in detail.
Two key issues were identified: firstly, to optimise the phosphoramidite reaction, a
highly soluble solvent for both the tri-N/O-acetylated cytidine and the activator is one
of the biggest challenges. After several trials, the tri-N/O-acetylated cytidine and the
activator showed good solubility in DMF/MeCN or DMF/THF solvent systems;
secondly, since SET is less reactive than 1H-tetrazole, a suitable ratio of triacetylated
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cytidine: SET: bis-amidite reagent is crucial for this phosphoramidite reaction. A low
ratio of triacetylated cytidine: activator: bis-reagent of 1: 1.2: 1.2 did not generate the
desired 5’-amidite (21), however, when the ratio was increased to 1: 2: 2, the desired
5’-amidite (21) was obtained, but also to the by-product (48).
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Part B
Synthesis of Sialyltransferase Transition-State Analogue
Inhibitors via the Phosphotriester Approach
4.5 Phosphotriester

approach

for

sialyltransferase

inhibitor

synthesis
4.5.1 Reported phosphotriester approach
The phosphotriester approach for oligonucleotide derivative preparation involves
three hydroxyl containing compounds reacting with the phosphorylating reagent
(phosphorus trichloride (PCl3) 23 and phosphoryl chloride (POCl3) 50) stepwise. It
can be regarded as a one-pot, three-step reaction, which dramatically reduces the
synthetic steps. Phosphorus trichloride (PCl3) 23 and phosphoryl chloride (POCl3) 50
are the two most important phosphorylating reagents used in the phosphotriester
approach. Based on these two phosphorylating reagents, it can be summarised in two
general pathways, which are the phosphite triester pathway starting using PCl3 and the
phosphate triester pathway utilising POCl3. In pathway A, the hydroxyl group in three
different components react with PCl3 step by step, generating a phosphite triester,
followed by oxidation from the phosphite triester to a phosphate triester. In pathway
B, the hydroxyl groups in the different synthons directly react with POCl3 without
further need for oxidation (see Figure 4.11).
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Figure 4.11 Two general synthetic pathways in the phosphotriester approach.

The synthesis of oligonucleotide derivatives via the phosphotriester approach has
a long history. In the early 1960s, Letsinger’s group firstly reported the phosphite
triester approach for preparing bioactive nucleotide phosphotriesters. Phosphite
coupling was firstly used to generate internucleotide links in early pioneering work on
DNA/RNA synthesis.[125, 126] In 1976, Letsinger et al. reported the synthesis of
thymidine oligonucleotides as nucleotide phosphotriesters, which offered a new
approach to generate a phosphorylating group linking two nucleosides. In this
approach, two nucleoside units were coupled by the highly reactive dichlorophosphite
reagent, followed by oxidation of the internucleotidic trivalent P-bond, generating the
required thymidine oligonucleotides derivatives.[126] Another branch of the
phosphotriester approach is the direct formation of a phosphate triester without a
phosphite intermediate from phosphorus trichloride (23). In 1989, McGuigan and his
colleagues reported a rapid 2-step approach for preparing phosphate triester
derivatives, where phosphoryl chloride (POCl3, 50) firstly reacted with an appropriate
alcohol with triethylamine as a base, followed by adding adenosine in dry pyridine,
providing a novel phosphate triester derivative in moderate yield.[127]
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4.5.2 Proposed phosphotriester synthetic pathway
The reported highly reliable and convenient phosphoramidite approach for
sialyltransferase inhibitors synthesis didn’t generate an ideal yield of the key 5’amidite intermediate (21) employing SET as a 1H-tetrazole alternative. Hence, it was
decided to try to prepare the sialyltransferase inhibitors 15a-i via a new proposed
phosphotriester approach.
Based on the structure of the novel sialyltransferase inhibitors, they can be
regarded as a kind of phosphate diester derivative which has a protected cytidine as a
synthon, and a α-hydroxyphosphonate derivative as the other synthon linked with a
phosphoryl group. Therefore, in the proposed phosphotriester approach, the three
hydroxyl groups in anhydrous benzyl alcohol, the dibenzyl α-hydroxyphosphonate
derivatives 17a-i and the tri-N/O-acetylated cytidine (18) react with the
phosphorylating reagent PCl3 step by step in the presence of base, generating the
phosphite triester intermediate (51a-i), followed by oxidation from phosphite 22a-i to
the phosphate triester (26). The desired sialyltransferase inhibitors are prepared by
deprotection

of

the

acetyl

and

benzyl

protecting

groups.

Dibenzyl

α-

hydroxyphosphonate derivatives 17a-i were chosen for coupling rather than the
diethyl α-hydroxyphosphonate derivatives 16a-i due to their ease of deprotection (see
Figure 4.12).[19, 128]
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Figure 4.12 Proposed new pathway for the synthesis of sialyltransferase inhibitors via the
phosphotriester approach.

4.5.3 Chosen synthetic method
4.5.3.1 Phosphite triester pathway A
The phosphite triester pathway employing PCl3 as the phosphorylating reagent is
shown in Figure 4.11, Pathway A. In many literature methods, MeOPCl2 (52) and
BnOPCl2 (53) are two important intermediates (see Figure 4.13). They are prepared
from PCl3 (23) reacting with MeOH or BnOH, respectively, and most of the time they
are prepared and used directly without further purification due to their highly reactive
nature, requiring argon or nitrogen atmosphere under low temperature.[58, 129]
Herein, MeOPCl2 (52) and BnOPCl2 (53) were employed due to several reasons.
Firstly, their starting material MeOH and BnOH are common reagents, only usually
requiring distillation from magnesium metal to be anhydrous before preparation;
secondly, the formed benzyloxydichlorophosphine or methoxydichlorophosphine are
still very reactive for coupling reactions (see Figure 4.13 and Table 4.4).
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Figure 4.13 Reported phosphotriester derivative syntheses via phosphite triester pathway A.

In 2007, Bhandari et al. reported the successful preparation of N-α-Fmoc-Omethyl phosphate L-serine (54) via a one-pot phosphotriester approach from PCl3.
Methanol was firstly added drop-wise to the solution of PCl3 in THF for 15 min at
0 °C, followed by adding 3-hydroxypropionitrile and Et3N drop-wise and stirring for
25 min at 0 °C. A solution of Fmoc-Ser-OH and Et3N in THF was added drop-wise to
the solution and stirred for 25 min at 0 °C. The residue was then oxidised by excess of
t-butyl hydroperoxide, and hydrolysed to the desired product in 32% yield (see Table
4.4, Reaction A).[56] In 1997, Hwu et al. discovered a new “one-flask” method to
prepare three taxol-containing aminophosphate derivatives. The hydroxyl group in the
large molecular compound taxol reacted with MeOPCl2 with collidine as a base in
THF, then introducing one molecular amino alcohol, followed by oxidation from
phosphite to phosphate in the presence of iodine, generating taxol-containing
aminophosphate derivatives in good yield.[130] In 2009, this “one-flask” method was
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used to prepare taxol-containning thiol phosphate (55) in three steps. Again, MeOPCl2
were used to couple taxol with PEG-SH, then oxidation of the phosphite centre,
followed by hydrolysis of protecting methyl group, providing the desired product in
72% yield (see Table 4.4, Reaction B).[57] In 2011, Zaffalon et al. reported
preparation of benzyloxydichlorophosphine (56) from PCl3 and benzyl alcohol, then it
was dissolved in THF with Et3N, the alcohol with a large hydrophobic part was added
drop-wise, followed by adding bromoethanol and oxidation. After deprotection of the
benzyl group, the bromoethanol was substituted by trimethyl amine, generating the
desired product in 2-10% overall yield (see Table 4.4, Reaction C). In 2007,
phosphitylation of the 1,2-diol of a sugar was achieved by reacting with highly
reactive benzyloxydichlorophosphine in the presence of excess Et3N, generating a
cyclic phosphate triester in 71% yield. The debenzylation of cyclic phosphate triester
was achieved by hydrogenation with Pt/C as catalyst, providing the final product (57)
in 98% yield (see Table 4.4, Reaction D).

Table 4.4 Reaction conditions reported in the literature for phosphotriester derivatives synthesised via
phosphite triester pathway A.
Reaction
A
B
C
D

Coupling
intermediate
MeOPCl2
MeOPCl2
BnOPCl2
BnOPCl2

Solvent

Base

THF
THF
THF
DCM

Et3N
collidine
Et3N
Et3N

Oxidation
reagent
t-BuOOH
I2
m-CPBA
t-BuOOH

Hydrolysis
reagent
DBU
H 2O
TFA
H2/Pt

Temp(°C)

Yield (%)

0
0
0
0

32
72
2-10
69

After comparison, Bhandari’s phosphotriester approach looks suitable for our
purposes due to reagent accessibility. Moreover, this one-pot phosphite triester
method doesn’t require purification of the intermediate, which was illustrated to be
highly reactive previously, and might lead to undesired by-products during
purification.
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4.5.3.2 Phosphate triester pathway B
Application of the POCl3 method offered another straightforward pathway for
oligonucleotide derivative synthesis via the phosphotriester approach. In 2010, a onepot phosphate triester synthesis from POCl3 was reported by Quintero et al., in which
a solution of POCl3 in DCM was added drop-wise into a solution of 2’,3’-Oisopropylidene-5-methyluridine and Et3N in DCM, with stirring for 2 hours, followed
by adding a solution of 1,3-diol and Et3N in DCM drop-wise and stirring for another 3
hours. The product (58) was purified by silica gel column chromatography, providing
a moderate yield (see Table 4.5, Reaction A).[100] This successful synthetic method
further confirmed the feasibility of both using the isopropylidene protected cytidine
modification and the proposed phosphotriester approach for the synthesis of the
sialyltransferase inhibitors.
In 2012, Caldarelli et al. reported the successful preparation of a cyclosal
phosphorylated prodrug from POCl3, where POCl3 was first reacted with
hydroxybenzoic acid generating the intermediate, followed by slow addition of the
disulfide prodrug, Et3N and DMAP in DCM. The reaction mixture was stirred
overnight at room temperature, and the desired product (59) was isolated in 53% yield
by silica gel chromatography (see Table 4.5, Entry 2).[131] As mentioned in chapter
3, Purohit et al. demonstrated an alternative pathway for introduction of the CMP
moiety, which was prepared using an isopropylidene protected cytidine reacting with
diethyl chlorophosphate with pyridine as solvent and base, generating the product (60)
in 67% yield (see Table 4.5, Entry 3).[97] After comparison, Quintero’s phosphate
triester approach was chosen due to its structural similarity with the desired novel
sialyltransferase inhibitors 15a-i.
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Table 4.5 Reported phosphotriester derivatives synthesis via phosphate triester pathway B.

Reaction
A
B
C

Solvent
DCM
DCM
Pyridine

4.6 Attempted

Base
Et3N
Et3N
Pyridine

synthesis

catalyst
DMAP
-

of

Temp (°C)
RT
RT
RT

Time
5h
16 h
2.5h

phosphotriester

22a

Yield (%)
31
53
67

via

the

phosphotriester approach.
The key intermediate MeOPCl2 (52) and BnOPCl2 (53) are quite reactive, with
purification requiring an argon/nitrogen atmosphere, and the crude product needing to
be kept at -15°C and best used directly used in the phosphotriester preparation.[57,
58, 129] Hence, Bhandari’s one-pot phosphite triester method and Quintero’s
phosphate triester method were followed to prepare the phosphotriester 22a. BnOH
(24) was chosen as the protecting alcohol rather than MeOH, due to it is ease of
deprotection (see Table 4.6).
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Table 4.6 Conditions trialled for the synthesis of phosphotriester (22a)

Reagents and conditions: Path A (i) BnOH (1 eq.), Et3N (1 eq.), THF, 0 °C, 15 min; (ii) 18 (1 eq.),
Et3N (1 eq.), THF, 0 °C, 2 h; (iii) 17a (1 eq.), Et3N (1 eq.), THF, RT, 6 h; (iv) t-BuOOH (2 eq.), THF,
RT, 16 h. Path B (i) BnOH (1 eq.), Et3N (1 eq.), THF, RT, 2 h; (ii) 18 (1 eq.), Et3N (1 eq.), THF, RT, 3
h; (iii) 17a (1 eq.), Et3N (1 eq.), THF, RT, 16 h.

Entry

Intermediate

Solvent

Temp

Addition time

Oxidation

1

Coupling
reagent
PCl3

BnOPCl2

0 °C

15 min

t-BuOOH

2
3

PCl3
POCl3

BnOPCl2
BnOPOCl2

THF,
MeCN
MeCN
MeCN

-20°C
RT

60 min
15 min

t-BuOOH
-

According to the procedure of Bhandari’s one-pot phosphite triester method [56],
one equivalent of anhydrous benzyl alcohol was added drop-wise into a solution of
PCl3 and Et3N during 15 min at 0°C under dry nitrogen, with a white precipitate
(Et3N·HCl) appearing during the addition. The reaction mixture was stirred for 15
min at 0°C to yield benzyloxydichlorophosphine. A solution of tri-N/O-acetylated
cytidine (18) and Et3N dissolved in MeCN was added drop-wise over a 15 min period,
and stirring continued at 0°C under dry nitrogen. However, TLC monitoring showed
that tri-N/O-acetylated cytidine (18) was not fully consumed even after 12 hours (see
Table 4.6, Entry 1). Next, a solution of dibenzyl hydroxyphosphonate 17a and Et3N
in THF was added drop-wise during 15 min to the reaction mixture, the reaction
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temperature was allowed to increase to room temperature and stirring continued for 6
hours. The reaction progress was monitored with TLC. The solvents were evaporated
under reduced pressure to give the phosphite triester 51a. Two equivalents t-butyl
hydroperoxide (in decane) in THF was added into the residue and stirred overnight, to
oxidise the phosphite triester 51a to phosphotriester 22a. After the reaction, crude
product was concentrated and analysed by MS. Instead of showing peaks for the
desired product, the by-product dibenzyl phosphonate (61) and unreacted tri-N/Oacetylated cytidine peak (18) were observed (see Figure 4.14).

Figure 4.14 MS of crude phosphate triester 22a (Table 4.6, Entry 1).

The by-product dibenzyl phosphonate (61) was isolated through silica gel column
chromatography from the reaction shown in Table 4.6, Entry 1. The structure of the
compound, obtained as a yellow liquid, was confirmed through

1

H NMR

spectroscopy. A distinctive doublet with a large coupling constant of 690 Hz appeared
at 6.9 ppm and was ascribed to the proton attached to phosphate group (HPO).
Aromatic protons with an integration of ten were observed at 7.28-7.31 ppm, while
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two methylene groups were observed from multiplets with an integration of four
protons between 4.99-5.08 ppm. In addition, a strong M+ Na+ peak at m/z= 285 in the
ESI+ spectrum, corresponding to the formula C14H15NaO3P, further confirmed the
structure.
The formation of by-product (61) and recovery of unreacted tri-N/O-acetylated
cytidine (18) suggested the conditions for adding the alcohol into the highly reactive
PCl3 is crucial in this kind of reaction, with addition time and temperature the two key
factors. In the method developed by Ducho et al. for preparing the cyclosal phosphate
triester, the solution of PCl3 was cooled to -20 °C to control the reactivity of
PCl3.[132] Moreover, the addition period of benzyl alcohol into PCl3 solution was
even increased to 5 hours to prepare crude benzyloxydichlorophosphine.[129] Based
on these reported procedures, the reaction was tried again as shown in Table 4.6,
Entry 2 with the following modifications: MeCN was chosen as solvent due to its
polarity. Benzyl alcohol was added into a solution of PCl3 at -20 °C over a one hour
period. However, the by-product was formed again as seen by MS and TLC analysis.
After two trials of preparation of phosphotriester 22a via the phosphite triester
approach, the phosphate triester method turned out to be more feasible due to the
following two advantages: firstly, it is more straightforward and avoids an oxidation
step comparing with the phosphite triester approach; and secondly, it is relatively less
reactive than the PCl3 approach, and therefore should be easier to control.
Therefore, the method discovered by Quintero et al.[100] was tried to prepare the
desired phosphotriester 22a (see Table 4.6, Entry 3). A solution of BnOH and Et3N in
MeCN was added drop-wise into POCl3 at room temperature and over a 15 min
period. The reaction mixture was allowed to react for 2 hours before adding a solution
of tri-N/O-acetylated cytidine (18) and triethylamine dissolved in MeCN, and then
stirred an additional three hours. A solution of dibenzyl hydroxyphosphate and
triethylamine was then added into the mixture and the reaction mixture stirred
overnight. After the reaction, MeCN was concentrated and the residue was purified by
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silica gel chromatography column. However, analysis by 1H NMR spectroscopy and
MS revealed starting material including benzyl alcohol, tri-N/O-acetylated cytidine
(18) and dibenzyl hydroxyphosphonate 17a remaining, presumably due to POCl3
being less reactive than PCl3. In the literature, derivatives such as (RO)2PCl and
(RO)PCl2 generally react very rapidly even at low temperature, in contrast,
(RO)2POCl

and

(RO)POCl2 required

longer

reaction

times

and

higher

temperatures.[126]

4.7 Summary of Part B
In conclusion, part B of chapter 4 presented a review of reported oligonucleotide
derivatives synthesised via the phosphotriester approach. After comparison of two
widely reported pathways used in the phosphotriester approach that utilise either PCl3
or POCl3, a new phosphotriester synthetic method was proposed to prepare the novel
sialyltransferase inhibitors 15a-i. After three attempts at preparing the desired
sialyltransferase inhibitors via the phosphotriester approach, a preliminary
understanding of the reactivity of the two phosphorylating reagent PCl3 and POCl3
was obtained. Even though the desired intermediate phosphotriester 22a was not
obtained due to time restraints, the phosphotriester approach suggested a new route to
obtain sialyltransferase inhibitors that has the potential to be cheaper, faster and more
efficient, however, still requires further development at this stage.
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5 CHAPTER 5
Biological Assays
At the outset of the project it was proposed to assess the α-hydroxyphosphonates
for enzyme inhibitory activity and the final target compounds in a cell-based assay for
cytotoxicity towards cancer cell lines, as well as in an enzyme assay against specific
sialyltransferases. However, as the target compounds were not reached only testing on
the α-hydroxyphosphonates was performed. α-Hydroxyphosphonates exhibit a wide
range of biological activities and are known to inhibit a raft of enzymes. Herein,
protein kinase A was chosen as the target enzyme for the α-hydroxyphosphonates as it
is an important target in a number of diseases and is already established and widely
used in our research group.

5.1 Protein kinase A assay
5.1.1 Protein kinase
Protein kinases are an abundant group of enzymes that catalyse the transfer of a
phosphate group from adenine triphosphate (ATP) to a hydroxyl-containing substrate.
Approximately 518 different human protein kinases were identified from the human
genome sequence in 2002.[133] Based on the specificity of their substrates, kinases
are divided into different families. The tyrosine kinases catalyse the phosphorylation
of the phenol group of tyrosine, while the transfer of phosphate to the hydroxyl group
of serine and threonine is mediated by serine-threonine kinases.[134] Protein kinases
play a central role in regulation of cellular activities and particularly in mediation of
signal transmission pathways. Moreover, they are important in a number of
physiological processes such as cell differentiation, proliferation, metabolism, DNA
damage repair, cell motility and apoptosis.[135] As a result, deregulation of kinases
has been found to be the main cause of a number of diseases, including oncological
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diseases, central nervous system disorders, autoimmune diseases, post-transplant
immunosuppression and osteoporosis.[136] c-AMP Dependent protein kinase A
(protein kinase A, PKA) is a member of the protein kinase family, and was reported to
mediate a number of physiological process including cardiovascular function, steroid
biosynthesis, reproductive function, memory process and immune function.[137-139]
Herein, a series of selected diethyl α-hydroxyphosphonate derivatives (16a, 16ci), α-hydroxyphosphonate derivatives (17a, 17c-e and 17g-i) and the deprotected
phosphonic acid (29) were tested for their inhibitory properties against c-AMP
dependent protein kinase A.

5.1.2 PKA inhibition assay
The Promega Kinase-Glo® luminescent assay was employed, to evaluate the PKA
inhibitory activity of a series of selected diethyl α-hydroxyphosphonate derivatives
(16a, 16c-i), dibenzyl α-hydroxyphosphonate derivatives (17a, 17c-e and 17g-i) and
deprotected phosphonic acid (29) prepared in Chapter 2 (see Table 2.2 for full
structures). This homogeneous and high-throughput assay measures the kinase
activity, by employing luminescence to quantify the amount of remaining ATP after a
kinase-catalysed reaction (see Figure 5.1).[140] The kinase substrate (such as
kemptide in case of PKA) and ATP react with the kinase to generate the
phosphorylated product and ADP (see Figure 5.1, Reaction 1). This step is followed
by adding the Kinase-Glo® reagent, which contains the substrate beetle luciferin and
buffer for the luciferase reaction. In this step, any remaining ATP after reaction 1 will
react with bettle luciferin in the presence of luciferase to produce oxyluciferin and one
photon of light per turnover (see Figure 5.1, Reaction 2). Thus, the amount of light
(luminescence) produced overall is directly proportional to the amount of enzyme
inhibition, as the more enzyme inhibition, the more residual ATP and thus more of
reaction 2 occurring and more light.
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Figure 5.1 Protocol of reactions in the Kinase-Glo® luminescent assay

Staurosporine (62) (IC50= 23 nM) or the quinolone sulphonamide H89 (63)
(IC50= 135 nM) are two well-known potent PKA inhibitors. In our PKA assay,
staurosporine (62) was employed as an internal standard, along with positive (100%
inhibition) and negative (0% inhibition) controls containing just the enzyme without
and with the substrate, respectively. All measurements were performed in triplicate.

Figure 5.2 The known PKA inhibitors, staurosporine (62) and H89 (63)

5.2 Biological assay results
All of the compounds tested (16a, 16c-i, 17a, 17c-e, 17g-i and 29) exhibited PKA
inhibitory activity between 85-100% as a percentage of the internal control
(staurosporine 62) (see Table 5.1). However, this is the first preliminary assay for
these compounds and there was an issue with the negative control registering higher
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values than expected. This assay needs to be repeated, however, due to the time
restraints, it was only able to be performed once. The current results appear to suggest
that all the tested compounds showed inhibitory activity at 100 μg/mL. However,
differences in inhibition activity that would have been expected due to the different
functional group substitutions, were not observed, which provides further evidence
that there was a likely problem with the assay, and the assay needs to be repeated. The
next step would be testing the IC50 (half maximal inhibitory concentration) values of
the most active compound, which can be determined by testing inhibitory activity at a
range of 6-8 different concentrations, rather just a single point determination.

Table 5.1 PKA inhibitory activity of tested compounds as a percentage of the internal control
(staurosporine 62)
Compound

% inhibition

Compound

% inhibition

16a

85 ± 2

17a

88 ± 4

16c

90 ± 3

17c

98 ± 5

16d

92 ± 6

17d

90 ± 3

16e

88 ± 4

17e

89 ± 2

16f

90 ± 2

17g

96 ± 4

16g

95 ± 6

17h

98 ± 3

16h

100 ± 2

17i

95 ± 1

16i

90 ± 3

29

85 ± 3
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6 CHAPTER 6
Conclusions and Future Directions
6.1 Conclusions
Significant progress was made towards the synthesis of a series of novel
sialyltransferase transition-state analogue inhibitors as potential anti-metastasis drugs.
As discussed in the introduction, the proposed sialyltransferase transition-state
inhibitors 15a-i comprise three key fragments: an α-hydroxyphosphonate derivative,
the protected cytidine component and the key phosphoryl linkage.
Nine diethyl α-hydroxyphosphonate derivatives 16a-i, nine dibenzyl αhydroxyphosphonate derivatives 17a-i and one hydroxyphosphonic acid (29), were
prepared in an efficient, inexpensive and readily accessible method, as key
components of the sialyltransferase inhibitors. Six of these compounds were novel
and another two were novel at the commencement of the project, but were published
during the year. Biological evaluation of the α-hydroxyphosphonate derivatives
showed that selected examples exhibited promising protein kinase A inhibitory
activity of 85-100% when tested at 100 µg/ml.
In terms of the protected cytidine moiety, based on a classical three step
preparation method, a large scale (overall more than 10 g) of the tri-N/O-acetylated
cytidine (18) was obtained as the key precursor in a highest overall yield of 64%. The
two intermediate products, the silyl protected cytidine (31) and silyl protected tri-N/Oacetylated cytidine (32), were fully characterised and their reaction conditions were
modified to obtain excellent yields of product (>90%).
However, the three step synthesis of the tri-N/O-acetylated cytidine (32) was a
high cost approach due to the solvent and column usage. The method usually took 3-4
days to give the desired protected cytidine and it required three column
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chromatography purification steps. The protection of the 2’- and 3’-hydroxyl groups
of cytidine with an isopropylidene group offered a new route for protecting the
cytidine. The 2’, 3’-O-isopropylidene-cytidine (33) can be obtained in a good yield of
78% in single day. Using this approach dramatically simplified the complex steps and
reduced the time and cost of preparing a protected cytidine fragment (see Figure 6.1).

Figure 6.1 Comparison of two protection approaches of cytidine.

To introduce the key phosphoryl linkage that links the α-hydroxyphosphonate
derivatives 16a-i and 17a-i with the protected cytidine component (18), two different
approaches were tried to generate the desired sialyltransferase transition-state
inhibitors 15a-i.
In the phosphoramidite approach to preparing the sialyltransferase inhibitors,
SET was chosen as an activator to overcome the difficulty resulting from the lack of
1H-tetrazole here in Australia. The 5’-amidite (21) was eventually successfully
prepared under modified conditions. Moreover, the by-product (48) was characterised,
and a critical analysis was given for explanation of the formation of by-product (48)
and the low yield of the desired product. Solubility of the reactants and the efficiency
of activator were the two major issues.
Furthermore, a new phosphotriester synthetic method was proposed and tried to
prepare the sialyltransferase transition-state analogue inhibitors, after a detailed
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review of phosphotriester based synthesis of oligonucleotide derivatives. Even though
the final product was not obtained due to time restraints, the phosphotriester approach
provided a new, concise and potentially improved way to generate the key phosphoryl
linkage.

6.2 Future directions
Future work on this project could involve the further examination of the
bioactivity of the α-hydroxyphosphonate derivatives 16a-i and 17a-i. These
compounds are planned to be tested against a range of human cancer cell lines to
obtain cytotoxicity data. At the time of writing, these studies were underway by in
collaboration with researchers at the Illawarra Health and Medical Research Institute.
Future studies on the preparation of sialyltransferase transition-state inhibitors 15a-i
could employ 2’, 3’-O-isopropylidene-cytidine (33) prepared in one-step, as the
protected cytidine moiety. Alternatively, other less polar protected cytidine moieties
such as tri-N/O-benzyl cytidine could be prepared, to improve the solubility for
preparation of the coupling reaction.
For the phosphoramidite approach, more efficient activators could be used to
improve the yield of the key intermediate 5’-amidite (21) and avoid generating the
troublesome by-product. On the other hand, low temperatures and addition control
can be used to control the reactive phosphorylating reagent PCl3 in the synthesis of
the inhibitors via the phosphotriester approach.
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Experimental
7.1 Chemical procedures
7.1.1 General
All chemical reactions were performed using standard laboratory equipment and
glassware. All chemicals were purchased from Sigma-Aldrich Chemical Co. or
Carbosynth Ltd. and used as supplied. All the solvents used were AR grade.
Anhydrous/ dry solvents were obtained from a dry solvent dispenser, Innovative
Technology PureSolv, model number PS-MD-5, 2007. Anhydrous DMF was replaced
with 99.8% DMF, which was purchased from Sigma-Aldrich Chemical Co.
Anhydrous acetone was further purified from commercially available acetone drying
with potassium carbonate for one day and molecular sieves overnight. Organic solvent
extracts/fractions were dried over magnesium sulphate. Solvent removal was
performed (in vacuo) using a Büchi R-114 or R200 rotary evaporator at temperatures
not greater than 45oC to avoid decomposition of samples.

7.1.2 Chromatography
Thin layer chromatography (TLC) on aluminium backed sheets of Merck Silica
Gel 60 F254 plates was employed to monitor the progress of chemical reactions. In
general, most compounds were colourless and were detected by exposure to UV light
at λ 254 nm. Column chromatography was performed on silica gel 60 (230- 400
mesh) using slight vacuum pressure. The solvent used in individual chromatographic
experiments is indicated and all solvent proportions are indicated as volume/volume
ratios.
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7.1.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Varian
Inova 500 MHz spectrometer. Proton (1H) and carbon (13C) spectra were obtained at
500 MHz and 125 MHz respectively. All spectra were acquired with a probe
temperature of 298 K. Spectra were recorded in deuterated solvent indicated in each
sample and were referenced to the residual non-deuterated solvent signal. Chemical
shifts (δ) were measured in parts per million (ppm), while coupling constants were
measured in Hertz (Hz). Subscript letters indicate interchangeable assignments.
Multiplicities are denoted as singlet (s), broad singlet (bs), doublet (d), broad doublet
(bd), doublet of doublets (dd), triplet (t), doublet of doublet of doublets (ddd), and
multiplet (m). The arrangement of the 1H NMR spectral data is listed as: chemical
shift, followed in brackets by multiplicity, coupling constant(s), integration and
ascribed assignment. The arrangement of the

13

C NMR spectral data is listed as:

chemical shift, followed in brackets by multiplicity, coupling constant(s) and ascribed
assignment.

7.1.4 Mass spectrometry
Low resolution electrospray ionization mass spectra (LRESI-MS) were obtained
using a Waters Platform LCZ spectrometer. High resolution electron ionisation mass
spectra (HREI-MS) were obtained using a Fisons/VG autospec spectrometer
operating with an electron beam of 70 eV, with a source temperature of 250 oC and
perfluorokerosence (PFK) or leucine enkephalin (LeuEnk) as the internal standard.

7.1.5 Melting Points
Melting points were determined on a Reichert melting point apparatus.
Temperatures were recorded in degrees Celsius (oC).
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7.2 Experimental for Chapter 2
7.2.1 Synthesis of diethyl benzyl(hydroxy)phosphonate (16a)
Benzaldehyde

(18.8

mmol,

2.00

g,

1.92

mL),

diethylphosphonate (21.4 mmol, 2.81 g, 2.68 mL), and
triethylamine (42.8 mmol, 4.20 g, 5.67 mL) were added
together in a RBF and stirred overnight at RT. After 2 hours,
precipitate started forming. The reaction mixture was then filtered and washed with
cold diethyl ether. The white solid was then dried under high vacuum and finally
recrystallised from hot diethyl ether. The compound was collected as a white solid.
Yield = 3.31 g (72%). Rf = 0.16 (silica, EtOAc : Hex= 1.3 : 1). m.p. 78-80 oC (lit.[69]
m.p. 83-84 oC).
1

H NMR (CD3Cl, 500 MHz): δ 1.22 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.27 (t, J =

7.0 Hz, 3H, OCH2CH3), 3.94-4.07 (m, 4H, OCH2CH3), 5.02 (d, 2JP-H = 10.5 Hz, 1H,
CHOH), 7.29-7.49 (m, 5H, ArH).
LRESI-MS: m/z 267 [M + Na] +. The spectral data matched those reported.[69]

7.2.2 Synthesis of diethyl 4-methylbenzyl(hydroxy)phosphonate (16b)
p-Tolualdehyde

(4.16

mmol,

0.50

g,

0.46

mL),

diethylphosphonate (6.16 mmol, 0.85 g, 0.79 mL), and
triethylamine (12.2 mmol, 1.23 g, 1.68 mL) were added
together in a RBF and stirred overnight RT. The reaction
mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 × 10 mL),
dried over anhydrous MgSO4 and filtered. After the solvent was removed using a
rotary evaporator, the final product was further purified by washing with hexane. The
compound was collected as a white solid. Yield = 0.84 g (78%). Rf = 0.23 (silica,
EtOAc : Hex= 1 : 1). m.p. 101-102 oC (lit.[72] m.p. 98-100 oC).
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1

H NMR (CD3Cl, 500 MHz): δ 1.20 (t, J = 7.5 Hz, 3H, OCH2CH3), 1.26 (t, J =

7.5 Hz, 3H, OCH2CH3), 2.33 (s, 3H, PhCH3), 3.94-4.07 (m, 4H, OCH2CH3), 4.96 (d,
2

JP-H = 11.0 Hz, 1H, CHOH), 7.14-7.36 (m, 4H, ArH).
LRESI-MS: m/z 281 [M + Na] +. The spectral data matched those reported.[72]

7.2.3 Synthesis of diethyl 4-ethylbenzyl(hydroxy)phosphonate (16c)
4-Ethylbenzaldehyde (3.73 mmol, 0.50 g, 0.51 mL),
diethylphosphonate (5.60 mmol, 0.77 g, 0.72 mL), and
triethylamine (11.2 mmol, 1.13 g, 1.55 mL) were added
together in a RBF and stirred overnight at RT. The reaction
mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 ×10 mL),
dried over anhydrous MgSO4 and filtered. After the solvent was removed using a
rotary evaporator, the final product was further purified by washing with hexane. The
compound was collected as a white solid. Yield = 0.96 g (95%). Rf = 0.28 (silica,
EtOAc : Hex= 1 : 1). m.p. 46-47 oC (lit.[65] liquid).
1

H NMR (CD3Cl, 500 MHz): δ 1.22 (t, J = 7.5 Hz, 3H, OCH2CH3), 1.23 (t, J =

7.5 Hz, 3H, OCH2CH3),1.29 (t, J = 7.0 Hz, 3H, PhCH2CH3), 2.65 (q, J = 7.0 Hz, 2H,
PhCH2CH3), 3.94-4.09 (m, 4H, OCH2CH3), 4.98 (d, 2JP-H = 10.0 Hz, 1H, CHOH,),
7.19-7.40 (m, 4H, ArH).
LRESI-MS: m/z 295 [M + Na] +. The spectral data match those reported.[65]

7.2.4 Synthesis of diethyl 3,5-dimethoxybenzyl(hydroxy)phosphonate (16d)
3,5-Dimethoxybenzaldehyde (3.00 mmol, 0.50 g),
diethylphosphonate (3.30 mmol, 0.46 g, 0.43 mL), and
triethylamine (6.60 mmol, 0.67 g, 0.92 mL) were added
together in a RBF and stirred overnight at RT. The
reaction mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 ×
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10ml), dried over anhydrous MgSO4 and filtered. After the solvent was removed using
a rotary evaporator, the final product was further purified by washing with hexane.
The compound was collected as a white solid. Yield = 0.77 g (84%). Rf = 0.11 (silica,
EtOAc : Hex= 1.5 : 1). m.p. 99-100oC (lit.[73] m.p. 101-103 oC).
1

H NMR (CD3Cl, 500 MHz): δ 1.24 (t, J = 7.5 Hz, 3H, OCH2CH3), 1.28 (t, J =

7.5 Hz, 3H, OCH2CH3), 3.78 (s, 6H, PhOCH3), 3.96-4.08 (m, 4H, OCH2CH3), 4.95
(d, 2JP-H = 11.5 Hz, 1H, CHOH,), 6.40-6.66 (m, 3H, ArH).
LRESI-MS: m/z 327 [M + Na]+. The spectral data matched those reported.[73]

7.2.5 Synthesis of diethyl 3-nitrobenzyl(hydroxy)phosphonate (16e)
3-Nitrobenzaldehyde

(3.31

mmol,

0.50

g),

diethylphosphonate (6.62 mmol, 0.91 g, 0.85 mL), and
triethylamine (13.2 mmol, 1.33 g, 1.82 mL) were added
together in a RBF and stirred overnight at RT. The
reaction mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 ×
10 mL), dried over anhydrous MgSO4 and filtered. After the solvent was removed
using a rotary evaporator, the final product was further purified by washing with
hexane. The compound was collected as a light yellow solid. Yield = 0.90 g (94%). Rf
= 0.10 (silica, EtOAc : Hex= 1.5 : 1). m.p. 89-90oC (lit.[66] m.p. 94-95 oC).
1

H NMR (CD3Cl, 500 MHz): δ 1.27 (t, J = 7.5 Hz, 3H, OCH2CH3,), 1.29 (t, J =

7.5 Hz, 3H, OCH2CH3,), 4.09-4.15 (m, 4H, OCH2CH3), 5.15 (d, 2JP-H = 11.0 Hz, 1H,
CHOH,), 7.53-8.38 (m, 4H, ArH).
LRESI-MS: m/z 312 [M + Na]+. The spectral data matched those reported.[66]
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7.2.6 Synthesis of diethyl 3-hydroxybenzyl(hydroxy)phosphonate (16f)
3-Hydroxylbenzaldehyde

(4.09

mmol,

0.50

g),

diethylphosphonate (8.18 mmol, 1.13 g, 1.05 mL), and
triethylamine (16.4 mmol, 1.66 g, 2.27 mL) were added
together in a RBF and stirred overnight at RT. The reaction
mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 ×10 mL),
dried over anhydrous MgSO4 and filtered. The solvent was concentrated and the
residue purified by flash chromatography using Hex: EtOAc= 1:1 for elution
affording white solid. Yield = 0.97 g (92%). Rf = 0.31 (silica, EtOAc : Hex= 1 : 1).
m.p. 96-97oC (lit.[68] m.p. 96-97 oC).
1

H NMR (CD3Cl, 500 MHz): δ 1.16 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.26 (t, J =

7.0 Hz, 3H, OCH2CH3,), 3.81-4.12 (m, 4H, OCH2CH3), 4.94 (d, 2JP-H = 11.5 Hz, 1H,
CHOH,), 6.7-7.25 (m, 4H, ArH).
LRESI-MS: m/z 283 [M + Na]+. The spectral data matched those reported.[68]

7.2.7 Synthesis of diethyl 2-fluorobenzyl(hydroxy)phosphonate (16g)
2-Fluorobenzaldehyde (4.03 mmol, 0.50 g, 0.43 ml),
diethylphosphonate (4.43 mmol, 0.61 g, 0.57 mL), and
triethylamine (8.86 mmol, 0.87 g, 1.14 mL) were added
together in a RBF and stirred overnight at RT. The reaction
mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 ×10 mL),
dried over anhydrous MgSO4 and filtered. After the solvent was removed using a
rotary evaporator, the final product was further purified by washing with hexane. The
compound was collected as a colourless solid. Yield = 0.97 g (92%). Rf = 0.10 (silica,
EtOAc : Hex= 1 : 1). m.p. 62-63 oC.
1

H NMR (CD3Cl, 500 MHz): δ 1.21 (t, J = 7.0 Hz, 3H, OCH2CH3), 1.31 (t, J =

7.0 Hz, 3H, OCH2CH3), 4.04-4.17 (m, 4H, OCH2CH3), 5.38 (d, 2JP-H = 11.5 Hz, 1H,
CHOH,), 7.02-7.68 (m, 4H, ArH).
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13

C NMR (CD3Cl, 125 MHz): δ 159.8 (d, 1JF-C = 245.6 Hz, quaternary ArC2),

124.6 (d, 2JF-C = 13.4 Hz, quaternary ArC1), 129.5, 128.9, 124.1 (3×d, JF-C = 2.5 Hz,
3×ArCH), 114.9 (d, 2JF-C = 22.0 Hz, ArC3), 64.1 (d, 1JP-C = 164.4 Hz, CHP), 63.4 (d,
2

JP-C = 7.6 Hz, OCH2CH3), 63.1 (d, 2JP-C = 7.6 Hz, OCH2CH3), 16.2, 161.1 (2×s,

2×OCH2CH3).
LRESI-MS: m/z 285 [M + Na]+. HRESI-MS: m/z calcd for C11H17FO4P
[M+H]+: 263.0849; found 263.0847.

7.2.8 Synthesis of diethyl 3-fluorobenzyl(hydroxy)phosphonate (16h)
3-Fluorobenzaldehyde (4.03 mmol, 0.50 g, 0.43 ml),
diethylphosphonate (4.43 mmol, 0.61 g, 0.57 mL), and
triethylamine (8.86 mmol, 0.87 g, 1.14 mL) were added
together in a RBF and stirred overnight at RT. The reaction
mixture was hydrolysed by adding water (3 mL), extracted with EtOAc (3 ×10 mL),
dried over anhydrous MgSO4 and filtered. After the solvent was removed using a
rotary evaporator, the final product was further purified by washing with hexane. The
compound was collected as a white solid. Yield = 1.00 g (95%). Rf = 0.08 (silica,
EtOAc : Hex= 1 : 1). m.p. 58-59oC (lit.[65] liquid).
1

H NMR (CD3Cl, 500 MHz): δ 1.25 (t, J = 7.5 Hz, 3H, OCH2CH3), 1.28 (t, J =

7.5 Hz, 3H, OCH2CH3), 4.02-4.12 (m, 4H, OCH2CH3), 5.02 (d, 2JP-H = 11 Hz, 1H,
CHOH,), 6.98-7.35 (m, 4H, ArH).
LRESI-MS: m/z 285 [M + Na]+. The spectral data matched those reported.[65]

7.2.9 Synthesis of diethyl 4-fluorobenzyl(hydroxy)phosphonate (16i)
4-Fluorobenzaldehyde (4.03 mmol, 0.50 g, 0.44 mL),
diethylphosphonate (4.43 mmol, 0.61 g, 0.57 mL), and
triethylamine (8.86 mmol, 0.87 g, 1.14 mL) were added
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together in a RBF and stirred overnight at RT. The reaction mixture was hydrolysed
by water (3 mL), extracted with EtOAc (3 ×10 mL), dried over anhydrous MgSO4 and
filtered. After the solvent was removed under the rotary evaporator, the final product
was further purified by washing with hexane. The compound was collected as a
colourless solid. Yield = 0.99 g (94%). Rf = 0.07 (silica, EtOAc : Hex= 1 : 1). m.p.
56-57oC (lit.[65] m.p. 55-57 oC).
1

H NMR (CD3Cl, 500 MHz): δ 1.24 (t, J = 7.5 Hz, 3H, OCH2CH3), 1.27 (t, J =

7.5 Hz, 3H, OCH2CH3), 4.02-4.07 (m, 4H, OCH2CH3), 5.02 (d, 2JP-H = 10.5 Hz, 1H,
CHOH), 7.05-7.48 (m, 4H, ArH).
LRESI-MS: m/z 285 [M + Na]+. The spectral data matched those reported.[65]

7.2.10 Synthesis of dibenzyl benzyl(hydroxy)phosphonate (17a)
Benzaldehyde (4.72 mmol, 0.50 g), dibenzylphosphonate
(5.19 mmol, 1.36 g), and triethylamine (10.4 mmol, 1.05
g, 1.44 mL) were added together in a RBF and stirred
overnight at RT. The reaction mixture was hydrolysed by
adding water (3mL), extracted with DCM (3×10 mL), dried over anhydrous MgSO4
and filtered. After the solvent was removed using a rotary evaporator, the final
product was further purified by washing with hexane. The compound was collected as
a white solid. Yield = 1.73 g (88%). Rf = 0.24 (silica, EtOAc : Hex= 1 : 1). m.p. 115116oC (lit.[75] m.p. 117-118 oC).
1

H NMR (CD3Cl, 500 MHz): δ 4.84-4.96 (m, 4H, OCH2Ph), 5.04 (d, 2JP-H = 10.5

Hz, 1H, CHOH,), 7.20-7.46 (m, 15H, ArH).
LRESI-MS: m/z 391 [M + Na]+. The spectral data matched those reported.[75]
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7.2.11 Synthesis of dibenzyl 4-ethylbenzyl(hydroxy)phosphonate (17c)
4-Ethylbenzaldehyde (2.24 mmol, 0.30 g, 0.31 mL),
dibenzylphosphonate

(3.36

mmol,

0.88

g),

and

triethylamine (7.13 mmol, 0.72 g, 0.98 mL) were added
together in a RBF, 3 mL DCM was added as solvent, then
stirred overnight at RT. The reaction mixture was
hydrolysed by adding water (3 mL), extracted with DCM (3 ×10 mL), dried over
anhydrous MgSO4 and filtered. After the solvent was removed using a rotary
evaporator, the final product was further purified by washing with hexane. The
compound was collected as a white solid. Yield = 0.78 g (88%). Rf = 0.58 (silica,
EtOAc : Hex= 1 : 1). m.p. 71-72oC.
1

H NMR (CD3Cl, 500 MHz): δ 1.23 (t, J = 7 Hz, 3H, ArCH2CH3), 2.64 (q, J = 7

Hz, 2H, ArCH2CH3), 4.84-4.94 (m, 4H, OCH2Ph), 5.02 (d, 2JP-H = 10.5 Hz, 1H,
CHOH,), 7.13-7.37 (m, 14H, ArH).
13

C NMR (CD3Cl, 125 MHz), δ 144.6 (s, quaternary ArC4), 136.4, 136.3 (2×s, ,

quaternary ArC9/C16), 133.6 (s, quaternary ArC1), 128.7, 128.6, 128.5, 128.4, 128.2,
128.1, 127.5, 127.4 (14×ArCH), 70.8 (d, 1JP-C = 158.8 Hz, CHP), 68.7, 68.6 (2×d, 2JPC=

7.5 Hz, C8/C15), 28.8 (s, PhCH2CH3), 15.8 (s, PhCH2CH3).
LRESI-MS: m/z: 397 [M + H]+. HRESI-MS: m/z calcd for C23H26O4P [M + H]+:

397.1569; found 397.1565.

7.2.12 Synthesis of dibenzyl 3,5-dimethoxybenzyl(hydroxy)phosphonate (17d)
3,5-Dimethoxylbenzaldehyde (1.81 mmol, 0.30 g),
dibenzylphosphonate (1.99 mmol, 0.53 g), and
triethylamine (4.00 mmol, 0.40 g, 0.55 mL) were
added together in a RBF, 3 mL DCM was added as
solvent, then stirred overnight at RT. The reaction
mixture was hydrolysed by adding water (3 mL), extracted with DCM (3×10 mL),
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dried over anhydrous MgSO4 and filtered. After the solvent was removed using a
rotary evaporator, the final product was further purified by washing with hexane. The
compound was collected as a white solid. Yield = 0.77 g (92%). Rf = 0.07 (silica,
EtOAc : Hex= 1 : 1). m.p. 80-81oC.
1

H NMR (CD3Cl, 500 MHz): δ 3.69 (s, 6H, 2×OCH3), 4.92-5.00 (m, 4H,

OCH2Ph, 1H, CHOH), 6.39-6.60 (m, 3H, ArH), 7.22-7.37 (m, 10H, ArH).
13

C NMR (CD3Cl, 125 MHz), δ 160.8 (s, quaternary ArC3/C5), 138.9 (s,

quaternary ArC1), 136.3, 136.2 (2×s, quaternary ArC9/C16), 128.7, 128.6, 128.6,
128.5, 128.2, 128.1, 105.3, 105.2, 101.0 (13×ArCH), 71.3 (d, 1JP-C = 158.8 Hz, CHP),
68.9, 68.7 (2×d, 2JP-C = 7.5 Hz, C8/C15), 55.5 (s, 2×OCH3).
LRESI-MS: m/z: 451 [M + Na]+. HRESI-MS: m/z calcd for C23H25O6P [M +
Na]+: 451.1286; found 451.1290.

7.2.13 Synthesis of dibenzyl 3-nitrobenzyl(hydroxy)phosphonate (17e)
3-Nitrobenzaldehyde

(1.98

mmol,

0.30

g),

dibenzylphosphonate (2.20 mmol, 0.58 g), and
triethylamine (4.40 mmol, 0.45 g, 0.62 mL) were
added together in a RBF, 3 mL DCM was added as
solvent, then stirred overnight at RT. The reaction mixture was hydrolysed by water
(3mL), extracted with DCM (3 ×10 mL), dried over anhydrous MgSO4 and filtered.
After the solvent was removed under the rotary evaporator, the final product was
further purified by washing with hexane. The compound was collected as a light
yellow solid. Yield = 0.62 g (76%). Rf = 0.52 (silica, EtOAc : Hex= 1 : 1). m.p. 8788oC (lit.[65] m.p. 87- 89 oC).
1

H NMR (CD3Cl, 500 MHz): δ 4.84-5.05 (m, 4H, OCH2Ph), 5.07 (d, 2JP-H = 10.0

Hz, 1H, CHOH,), 7.28-8.25 (m, 14H, ArH).
LRESI-MS: m/z 436 [M + Na]+.The spectral data matched those reported.[65]
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7.2.14 Synthesis of dibenzyl 2-fluorobenzyl(hydroxy)phosphonate (17g)
2-Fluorobenzaldehyde (2.42 mmol, 0.30 g, 0.26 mL),
dibenzylphosphonate

(2.66

mmol,

0.70

g),

and

triethylamine (5.32 mmol, 0.54 g, 0.74 mL) were added
together in a RBF, 3 mL DCM was added as solvent, then
stirred overnight at RT. The reaction mixture was hydrolysed by adding water (3 mL),
extracted with DCM (3×10 mL), dried over anhydrous MgSO4 and filtered. After the
solvent was removed using a rotary evaporator, the final product was further purified
by washing with hexane. The compound was collected as a white solid. Yield = 0.67
g (72%). Rf = 0.57 (silica, EtOAc : Hex= 1 : 1). m.p. 75-76oC.
1

H NMR (CD3Cl, 500 MHz): δ 4.87-5.08 (m, 4H, OCH2Ph), 5.45 (d, 2JP-H = 11.0

Hz, 1H, CHOH,), 6.98-7.64 (m, 14H, ArH).
13

C NMR (CD3Cl, 125 MHz):  159.8 (d, 1JF-C = 246.8 Hz, quaternary ArC2),

136.0, 135.9 (2×s, quaternary ArC9/C16), 124.1 (d, 2JF-C = 15.3 Hz, quaternary ArC1),
115.1 (d, 2JF-C = 20.0 Hz, Ar C3), 129.8, 129.7, 129.1, 128.5, 128.4,127.8, 124.4,
124.3, 124.1, 129.0 (14×ArCH), 64.2 (d, 1JP-C = 162.1 Hz, CHP), 68.8, 68.5 (2×d, 2JPC=

6.3 Hz, C8/C15).
LRESI-MS: m/z 387 [M + H]+. HRESI-MS: m/z calcd for C21H21FO4P [M +

H]+: 387.1161; found 387.1150.

7.2.15 Synthesis of dibenzyl 3-fluorobenzyl(hydroxy)phosphonate (17h)
3-Fluorobenzaldehyde (2.42 mmol, 0.30 g, 0.26 mL),
dibenzylphosphonate

(2.66

mmol,

0.70

g),

and

triethylamine (5.32 mmol, 0.54 g, 0.74 mL) were added
together in a RBF, 3 mL DCM was added as solvent,
then stirred overnight at RT. The reaction mixture was hydrolysed by adding water (3
mL), extracted with DCM (3×10 mL), dried over anhydrous MgSO4 and filtered.
After the solvent was removed using a rotary evaporator, the final product was further
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purified by washing with hexane. The compound was collected as a white solid. Yield
= 0.68 g (73%). Rf = 0.55 (silica, EtOAc : Hex= 1 : 1). m.p. 78-79oC.
1

H NMR (CD3Cl, 500 MHz): δ 4.91-4.97 (m, 4H, OCH2Ph), 5.03 (d, 2JP-H = 10.5

Hz, 1H, CHOH), 6.99-7.33 (m, 14H, ArH).
13

C NMR (CD3Cl, 125 MHz): δ 162.7 (d, 1JF-C = 244.1 Hz, quaternary ArC3),

138.8, 138.7 (2×s, quaternary ArC9/C16), 135.8 (d, 3JF-C = 5.6 Hz, quaternary ArC1),
129.7, 129.7, 128.6, 128.5, 128.0, 122.8, 122.8, 115.0, 114.3, 114.1 (14×ArCH), 70.2
(d, 1JP-C = 158.4 Hz, CHP), 68.9, 68.6 (2×d, 2JP-C = 7.6 Hz, C8/C15).
LRESI-MS: m/z 387 [M + H]+. HRESI-MS: m/z calcd for C21H21FO4P [M +
H]+: 387.1161; found 387.1161.

7.2.16 Synthesis of dibenzyl 4-fluorobenzyl(hydroxy)phosphonate (17i)
4-Fluorobenzaldehyde (2.42 mmol, 0.30 g, 0.26 mL),
dibenzylphosphonate

(2.66

mmol,

0.70

g),

and

triethylamine (5.32 mmol, 0.54 g, 0.74 mL) were added
together in a RBF, then 3 mL DCM was added as the
solvent, and the reaction stirred overnight at RT. The reaction mixture was hydrolysed
by adding water (3 mL), extracted with DCM (3×10 mL), dried over anhydrous
MgSO4 and filtered. After the solvent was removed using a rotary evaporator, the final
product was further purified by washing with hexane. The compound was collected as
a white solid. Yield = 0.78 g (84%). Rf = 0.60 (silica, EtOAc : Hex= 1 : 1). m.p. 102104oC.
1

H NMR (CD3Cl, 500 MHz): δ 4.11 (s, 1H, CHOH), 4.88-5.01 (m, 4H, OCH2Ph,

1H, CHOH), 6.96-7.39 (m, 14H, ArH).
13

C NMR (CD3Cl, 125 MHz), δ 162.8 (d, 1JF-C = 245.2 Hz, quaternary ArC4),

136.2, 136.1 (2×s, quaternary Ar C9/C16), 132.1 (s, quaternary ArC1), 129.3, 129.1,
128.7, 128.6, 128.2, 128.5 115.6, 115.5, 115.4, 115.3 (14×Ar CH), 70.6 (d, 1JP-C =
156.4 Hz, CHP), 68.8, 68.6 (2×d, 2JP-C = 7.4 Hz, C8/C15).
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LRESI-MS: m/z 387 [M + H]+. HRESI-MS: m/z calcd for C21H21FO4P [M +
H]+: 387.1161; found 387.1160.

7.2.17 Synthesis of hydroxyl benzylphosphonic acid (29)
Method A: According to the method of McGeary et al.,[59] TMSCl
(1.11 g, 10.2 mmol) was added to a solution of the diethyl αhydroxyphosphonate 16a (0.50 g, 2.05 mmol) and KI (1.03 g, 6.15
mmol) in MeCN (2 mL) and the resulting suspension was stirred at
room temperature for 3.5 days. After removing the MeCN in vacuo, the residue was
partitioned between saturated NaHCO3 solution and hexane. The aqueous layer was
washed with hexane, and then acidified to pH 1 with 32% HCl. The acidified aqueous
layer was extracted with EtOAc. The organic layer was dried (MgSO4), and then
concentrated in vacuo, giving an orange amorphous solid in 10% yield.
Method B: According to the method of Dayde et al.,[76] diethyl αhydroxyphosphonate 16a (0.50 g, 2.05 mmol) was dissolved in DCM (10 mL), then
TMSBr (20.5 mmol, 2.2 mL) was added and the reaction mixture was stirred for 16
hours at room termperature. The reaction mixture was concentrated under vacuum, the
resulting white solid was dissolved in EtOAc and H2O, and then acidified to pH 1
with 32% HCl. The acidified aqueous layer was extracted with EtOAc. The organic
layer was dried (MgSO4), and then concentrated in vacuo, giving an orange
amorphous solid. Yield = 0.16 g (40%). m.p. 165-166 oC. (lit.[80] m.p. 168 oC).
1

H NMR (CD3OD, 500 MHz): δ 4.18 (d, 2JP-H = 13 Hz, 1H, CHOH), 7.25- 7.51

(m, 5H, ArH).
LRESI-MS: m/z 187 [M - H]-. The spectral data matched those reported.[80]
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7.3 Experimental for Chapter 3
7.3.1 Synthesis of N4–acetyl-1-(2’,3’-di-O-acetyl-5’-O-tert-butyldimethylsilyl -βD-arabinofuranosyl)cytosine (31)
Method A: According to the method of Rodríguez et al.,[86]
tert-butyldimethylsilyl

chloride

(0.36

g,

2.40

mmol),

anhydrous Et3N (400 μL, 3.10 mmol), and DMAP (0.045 g,
0.18 mmol) were added to a solution of cytidine (0.50 g, 2.10
mmol) in DMF (10 mL) and DCM (5 mL). The reaction was
stirred at room temperature for 16 hours. There was starting
material remaining as monitored by TLC, so the reaction was allowed to react for
another 32 hours. However, there was still starting material remaining. The reaction
was stopped and the solvents were concentrated under vacuum, and the crude product
was extracted with DCM. The residue was purified by flash chromatography using
(10%-20%) MeOH/CH2Cl2 for elution affording the compound as a white solid in
10% yield.
Method B: The preparation of this compound was attempted according to
Method A with the following modifications: DMF was used as the only solvent to
dissolve the starting cytidine material. The starting material was completely
consumed after 16 hours, generating the product in 35% yield.
Method C: The preparation of this compound was attempted according to
Method A with the following modifications: DMF was used as the only solvent, and it
was removed at 50 oC by rotary evaporator linking with high vacuum (<10 mbar)
after reaction. The product was not stable under this condition, and decomposed to
starting material as observed by TLC and MS examination.
Method D: According to the method of Debarge et al.,[84] tertbutyldimethylsilyl chloride (0.36 g, 2.40 mmol) and imidazole (0.28 g, 4.11 mmol)
were added to a solution of cytidine (0.50 g, 2.10 mmol) in DMF (10 mL). The
reaction was stirred at room temperature for 16 hours, then poured into crushed
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ice/water (20 mL). The white precipitate was collected by filtration as the desired
product in 24%.
Method E: The preparation of this compound was attempted according to
Method A with the following modifications: DMF was used as the only solvent to
dissolve the starting cytidine material, and the crude product was extracted with
EtOAc. The EtOAc layer was concentrated and the residue was purified by flash
chromatography using (10%-20%) MeOH/CH2Cl2 for elution affording the desired
compound as a white solid. Yield = 0.66 g (92%). Rf = 0.02 (silica, DCM:MeOH 9:1).
m.p. 160- 161oC (lit.[86] m.p. 162- 164 oC).
1

H NMR: (CD3Cl, 500 MHz): δ 0.08 (s, 6H, Si(CH3)2), 0.88 (s, 9H, C(CH3)3),

3.79 ( dd, 2JH-H = 10.5 Hz, J = 4.5 Hz, 1H, H5’a), 3.92 ( dd, 2JH-H = 10.5 Hz, J = 4.5
Hz, 1H, H5’b), 4.14-4.27 (m, 3H, H2’, H3’ & H4’), 5.85 (d, J = 7.5 Hz, 1H, H5), 5.95
(d, J = 3.7 Hz, 1H, H1’), 8.01 (d, J = 7.5 Hz, 1H, H6).
LRESI-MS: m/z 358 [M + H]+. The spectral data matched those reported.[86]

7.3.2 Synthesis of N4–acetyl-1-(2’,3’-di-O-acetyl-5’-O-tert-butyldimethylsilyl-β D-arabinofuranosyl)cytosine (32)
According to the method of Rodríguez et al.,[86] to a solution
of

1-(5’-O-tert-butyldimethylsilyl-β-D-arabinofuranosyl)

cytosine (0.46 g, 1.29 mmol) in pyridine (4.20 mL) at 0 oC
was added acetic anhydride (0.90 mL, 9.50 mmol). After
being stirred at room temperature for 15 hours, the mixture
was poured into 30 mL saturated aqueous NaHCO3 solution
and extracted with 3×30 ml EtOAc. The combined organic fractions were dried
(MgSO4) and concentrated under vacuum. Toluene was added into the concentrated
solvent to remove pyridine by sequential evaporation. The crude was purified by flash
chromatography using 80-100% EtOAc/Hexane gradient elution to obtain the desired
product as a white foam. Yield = 0.57 g (92%). Rf = 0.26 (silica, Hex: EtOAc= 1:4).
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m.p. 230-231oC (lit.[86] m.p. 229- 231 oC).
1

H NMR: (CD3Cl, 500 MHz): δ 0.13 (s, 6H, Si(CH3)2), 0.93(s, 9H, C(CH3)3),

2.06 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.27 (s, 3H, CH3), 3.82 (dd, 2JH-H = 10.5 Hz, J =
4.5 Hz, 1H, H5’a), 3.98 (dd, 2JH-H = 10.5 Hz, J = 4.5 Hz, 1H, H5’b), 4.27 (q, J = 4.5
Hz, 1H, H4’), 5.35-5.38 (m, 2H, H2’, H3’), 6.35 (d, J = 4.5 Hz, 1H, H1’), 7.38 (d, J =
7.5 Hz, 1H, H5), 8.31 (d, J = 7.5 Hz, 1H, H6).
LRESI-MS: m/z 506 [M + Na]+. The spectral data matched those reported.[86]

7.3.3 Synthesis
of
cytosine (18)

N4–acetyl-1-(2’,3’-di-O-acetyl-5’-β-D-arabinofuranosyl)

According to the method of Rodríguez et al.,[86] acetic acid
(95.0 μL, 1.71 mmol) and TBAF (3.42 mL, 1 M in THF, 3.42
mmol) were added to a solution of N4-acetyl-1-(2’,3’-di-Oacetyl-5’-O-tert-butyldimethylsilyl-β-

D-arabinofuranosyl)

cytosine (0.55 g, 1.14 mmol) in anhydrous THF (9.7 ml) at 0
o

C, and the reaction was stirred at 0 oC for 2 h. The mixture was concentrated and the

residue purified by flash chromatography using MeOH/CH2Cl2/Et2O= 1:8:1 for
elution affording a white foam. Yield = 0.32 g (76%). Rf = 0.25 (silica, MeOH :
CH2Cl2 : Et2O= 1:8:1). m.p. 172-173 oC (lit.[86] m.p. 173- 175 oC).
1

H NMR: (CD3Cl, 500 MHz): δ 2.07 (s, 3H, CH3), 2.11 (s, 3H, CH3), 2.27 (s, 3H,

CH3), 3.84 (dd, 2JH-H = 10.5 Hz, J = 4.5 Hz, 1H, H5’), 4.00 (dd, 2JH-H = 10.5 Hz, J =
4.5 Hz, 1H, H5’’), 4.26 (q, J = 4.5 Hz, 1H, H4’), 5.50 (t, J = 4.5 Hz, 1H, H3’), 5.59 (t,
J= 4.5 Hz, 1H, H2’), 6.03 (d, J = 4.5 Hz, 1H, H1’), 7.47 (d, J = 7.5 Hz, 1H, H5), 8.26
(d, J = 7.5 Hz, 1H, H6).
LRESI-MS: m/z 392 [M + Na] +. The spectral data matched those reported.[86]
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7.3.4 Synthesis of 2’,3’-O-isopropylidene-cytidine (33)
Method A: According to the method of Thirumalairajan et
al.,[96] to a solution of cytidine (0.50 g, 2.05 mmol) and a
catalytic amount of p-toluenesulfonic acid (TsOH· H2O, 0.04
g, 0.2 mmol) in acetone (25 mL), 2,2-dimethoxypropane (0.28
ml, 0.24 g, 2.3 mmol) was added at 0 oC. The suspension was
slowly heated to a gentle reflux for 12 hours. The solution
was then cooled to room temperature and treated with sodium bicarbonate (0.03 g,
0.36 mmol) and stirred at room temperature for an additional 0.5 hour. Analysis by
TLC revealed the crude product contained starting material. The solid was filtered and
the filtrate was adsorbed on silica gel and purified by flash chromatography. Analysis
by MS and 1H NMR spectroscopy revealed no desired product.
Method B: According to the method of Purohit et al.,[97] a suspension of
cytidine (500 mg, 2.05 mmol) in anhydrous acetone (40 mL) was cooled to 0 °C.
Then, conc. H2SO4 (0.25 mL) was added drop-wise into the suspension. After stirring
at room temperature for 12 h, the reaction mixture was neutralized by NH4OH.
Analysis by TLC and 1H NMR spectroscopy revealed the crude product contained
starting material and no desired product.
Method C: According to the method of Lusic et al.[98] to a suspension of
cytidine (0.50 g, 2.05 mmol) in 25 mL of acetone was added 2,2-dimethoxypropane
(3 mL, 2.05 g, 24.5 mmol). 70% HClO4 was then added dropwise until the solution
turned clear. The reaction mixture was stirred at room temperature for 2 hours, after
which it was neutralized by addition aqueous ammonia (28%, 1.5 mL), the mixture
was concentrated and the residue was purified by flash chromatography using (10%)
MeOH/CH2Cl2 with 2% TEA for elution affording a white solid. Yield = 0.45 g
(78%). Rf = 0.25 (silica, MeOH : CH2Cl2 = 1 : 9). m.p. 220-222 oC (lit.[98] m.p. 224
o

C).
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1

H NMR: (CD3OD, 500 MHz): δ 1.33 (s, 3H, iso CH3), 1.53 (s, 3H, iso CH3),

3.68 ((dd, 2JH-H = 12.0 Hz, J = 4.0 Hz, 1H, H5’a), 3.75 (dd, 2JH-H = 12.0 Hz, J = 4.0
Hz, 1H, H5’b), 4.16 (q, J = 4.0 Hz, 1H, H4’), 4.84-4.87 (m, 2H, H2’, H3’), 5.78 (d, J
= 2.5 Hz ,1H, H1’), 5.88 (d, J = 7.5 Hz, 1H, H5), 7.80 (d, J = 7.5 Hz, 1H, H6).
LRESI-MS: m/z 306 [M + Na]+.The spectral data matched those reported.[98]
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7.4 Experimental in Chapter 4
7.4.1 Synthesis
of
2-cyanoethyl-2’,3’-O,N4-tri-acetylcytidin-5’-yl-N,Ndiisopropylphosphoramidite (21)
Method A: According the method of Kajihara et al.,[109] to
a solution of tri-N/O-acetylated cytidine 18 (0.10 g, 0.27
mmol), N,N,N',N'-tetraisopropylphosphorodiamidite (0.16 g,
0.54 mmol), and diisopropylamine (0.08 mL, 0.54 mmol) in
dry MeCN (20 mL) and DMF (8 mL) was added 5ethylthio-lH-tetrazole (0.07 g, 0.54 mmol) at 0 oC, and the mixture was then stirred
for 12 hours at room temperature. The mixture was diluted with EtOAc and washed
with NaHCO3 solution. After being dried with MgSO4, the mixture was concentrated
and the residue was purified by flash chromatography using MeOH/EtOAc = 1: 19
with 5% TEA for elution affording a yellow oil as a diastereomeric mixture. Yield =
0.05 g (30%, containing a small of amount by-product 45). Rf = 0.60 (silica, MeOH :
EtOAc = 1 : 19).
1

H NMR: (CD3Cl, 500 MHz): δ 1.25 (d, J = 7.0 Hz, 6H, CH(CH3)2), 1.27 (d, J =

7.0 Hz, 6H, CH(CH3)2), 2.05, 2.06 (2×s, 3H, OCOCH3)≠, 2.09, 2.10 (2×s, 3H,
OCOCH3) ≠, 2.24 (s, 3H, NHCOCH3), 2.62-2.70 (m, 2H, H2’’a, H2’’b), 3.46-4.25 (m,
6H, 2×CH(CH3)2, H5’a, H5’b &H1’’a, H1’’b), 4.33-4.36 (m, 1H, H4’), 5.34-5.46 (m,
2H, H2’, H3’), 6.30 (2×d, J = 5.5 Hz, 1H, H1’) ≠, 7.41, 7.42(2×d, J = 7.5 Hz, 1H, H5)
≠

, 8.23, 8.24 (2×d, J = 7.5 Hz, 1H, H6) ≠.
LRESI-MS: m/z 592 [M + Na]+.

≠

Diastereomers observed due to the chiral phosphate.
Method B: The preparation of this compound was attempted according to

Method A with the following modifications: DCM was used as the only solvent,
however, DCM didn’t dissolve the starting tri-N/O-acetylated cytidine 18 and the
tetrazole diisopropylammonium salt (which is formed by SET and diisopropylamine).
Analysis by TLC and 1H NMR spectroscopy revealed the crude reaction product
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contained the starting material 18 and no desired product.
Method C: The preparation of this compound was attempted according to
Method A with the following modifications: MeCN was used as the only solvent.
MeCN did dissolve the starting tri-N/O-acetylated cytidine 18, but did not dissolve the
tetrazole diisopropylammonium salt (which is formed by SET and diisopropylamine).
Analysis by TLC and 1H NMR spectroscopy revealed the crude product contained
starting material 18 and no desired product.
Method D: The preparation of this compound was attempted according to
Method A with the following modifications: THF and DMF were used as a mixed
solvent system. To tri-N/O-acetylated cytidine 18 (0.12 g, 0.33 mmol), bis-amidite
reagent 19 (0.20 g, 0.66 mmol), and diisopropylamine (0.10 ml, 0.66 mmol) in dry
THF (20 mL) and DMF (8 mL) was added 5-ethylthio-lH-tetrazole (0.09 g, 0.66
mmol), and the reaction mixture was then stirred for 12 hours at room temperature. A
mixture of desired product and a small amount by-product 45 was obtained after flash
column chromatography purification. Yield = 0.08 g (45%, containing a small of
amount by-product 45).
Method E: The preparation of this compound was attempted according to
Method D with the following modifications: DCM and DMF were used as a solvent
system instead of THF and DMF. tri-N/O-acetylated cytidine 18 (0.07 g, 0.18 mmol),
bis-amidite reagent 19 (0.11 g, 0.36 mmol), and diisopropylamine (0.05 ml, 0.36
mmol) in DCM (20 mL) and DMF (8 mL) was added 5-ethylthio-lH-tetrazole (0.05 g,
0.36 mmol), and the reaction mixture was then stirred for 12 hours at room
temperature. A mixture of desired product and a small amount by-product 45 was
obtained after flash column chromatography purification. Yield = 0.02 g (20%,
containing a small of amount by-product 45).
Method F: The preparation of this compound was attempted according to
Method A with the following modifications: THF and DMF were used as a solvent
system. A ratio of tri-N/O-acetylated cytidine 18: SET: bis-amidite reagent 19= 1: 1.2:
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1.2 was utilised without diisopropylamine. Analysis by TLC and

1

H NMR

spectroscopy revealed the crude product contained starting material 18 and no desired
product.
Method G: The preparation of this compound was attempted according to
Method A with the following modifications: THF and DMF were used as the solvent
system. A ratio of tri-N/O-acetylated cytidine 18: SET: bis-amidite reagent 19:
diisopropylamine = 1: 1.2: 1.2: 1.2 was utilised. Analysis by TLC and 1H NMR
spectroscopy revealed the crude product contained starting material 18 and no desired
product.
Method H: The preparation of this compound was attempted according to
Method G with the following modifications: A ratio of tri-N/O-acetylated cytidine 18:
SET: bis-amidite reagent 19: diisopropylamine = 1: 1.5: 1.5: 1.5 was utilised.
Analysis by TLC and 1H NMR spectroscopy revealed the crude product contained
starting material 18 and no desired product.

7.4.2 Attempted
synthesis
methylphosphite (47)

of

2-cyanoethyl

bis(3,4-dimethoxybenzyl)

Method A: This compound was prepared according the
method reported by Kajihara et al.[109] with ratio of 3,4dimethoxybenzyl alcohol 46: SET: bis-amidite reagent
19: diisopropylamine = 1: 1.2: 1.2: 1.2. To a solution of
3,4-dimethoxybenzyl alcohol (0.04 ml, 0.30 mmol), bisamidite

reagent

19

(0.11

g,

0.36

mmol)

and

diisopropylamine (0.05 mL, 0.36 mmol) in dry MeCN (20 mL) and DMF (8 mL) was
added 5-ethylthio-lH-tetrazole (0.05 g, 0.36 mmol) and the mixture was then stirred
for 12 hours at room temperature. The mixture was diluted with EtOAc and washed
with NaHCO3 solution. The EtOAc layer was collected and dried with MgSO4.
Analysis by TLC and 1H NMR spectroscopy revealed the crude product contained
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starting material 46 and no desired product.
Method B: The preparation of this compound was attempted according to
Method A with the following modifications: A ratio of 3,4-dimethoxybenzyl alcohol
46: SET: bis-amidite reagent 19: diisopropylamine = 1: 1.5: 1.5: 1.5 was utilised.
Analysis by TLC and 1H NMR spectroscopy revealed the crude product contained
starting material 46 and no desired product.
The by-product 2-cyanoethyl bis(3,4-dimethoxy
benzyl) phosphite 48 was obtained after flash
chromatography of the reaction product from the
attempted

phosphoramidite

47

preparation

(Method B). A yellow oil was obtained. Yield =
0.04 g (31%). Rf = 0.64 (silica, EtOAc : Hex = 1 :
1).
1

H NMR (CD3Cl, 500 MHz): δ 2.54 (t, J = 7.0 Hz, 1H, OCH2CH2CN, H2’’a),

2.55 (t, J = 7.0 Hz, 1H, OCH2CH2CN, H2’’b), 3.85 (s, 6H, Ph(OCH3)2), 3.86 (s, 6H,
Ph(OCH3)2), 3.94 (t, J = 7.0 Hz, 1H, OCH2CH2CN, H1’’a), 3.95 (t, J = 7.0 Hz, 1H,
OCH2CH2CN, H1’’b), 4.81 (s, 2H, OCH2Ph, H7’), 4.83 (s, 2H, OCH2Ph, H7), 6.816.88 (m, 6H, ArH).
LRESI-MS: m/z 458 [M + Na]+.
The by-product 45 was was obtained after flash chromatography
in the model reactions. Rf = 0.55 (silica, MeOH : EtOAc = 1 :
19)
1

H NMR: (CD3Cl, 500 MHz): δ 1.21 (d, J = 7.0 Hz, 6H,

CH(CH3)2), 1.22 (d, J = 7.0 Hz, 6H, CH(CH3)2), 2.71 (t, J = 6.0 Hz, 1H, H2a), 2.73 (t,
J = 6.0 Hz, 1H, H2’b), 3.46 (sept, J = 7.0 Hz, 1H, CH(CH3)2), 3.49 (sept, J = 7.0 Hz,
1H, CH(CH3)2), 4.07 (t, J = 6.0 Hz, 1H, H1a), 4.16 (t, J = 6.0 Hz, 1H, H1’b), 6.90 (d,
1

JP-H = 625.0 Hz, 1H, HPO).
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LRESI-MS: m/z 219 [M + H]+.

7.4.3 Attempted synthesis of triethylammonium(2’,3’-O,N4-tri-acetylcytidin -5’yl-)-(1-dibenzyl phosphonato-2-phenylethyl)-phosphate (49).
5’-Amidite (21) (0.08g, 0.14 mmol), and dibenzyl αhydroxyphosphonate 17a (0.06g, 0.15 mmol) were
evaporated and dried under vacuum. The remaining
foam was dissolved in dry CH2Cl2, and SET (0.04g,
0.28 mmol) was added and kept stirring. All the 5’amidite (21) was consumed after three hours
monitored by TLC. Followed by adding 0.1 ml t-BuOOH (5.0- 6.0 M in decane), and
stirred for an additional hour. NEt3 (50 eq.) were then added, and stirred for a further
18 h, the reaction mixture was concentrated and the residue purified by silica gel flash
chromatography. Analysis by 1H NMR spectroscopy and MS revealed several
unidentified products but none of the expected product.

7.4.4 Attempted synthesis of phosphotriester (22a)
Method A: According to the method reported by
Bhandari et al.[56], phosphorus trichloride (0.02
mL, 0.21 mmol) and triethylamine (0.04 mL, 0.21
mmol) were added to anhydrous THF (5 mL) under
dry nitrogen. Benzyl alcohol (0.02 mL, 0.21 mmol)
was added drop-wise over a 15 min period to the
solution, and the mixture was stirred for an additional 15 min at 0°C. A solution of triN/O-acetylated cytidine 18 (80.0 mg, 0.021 mmol) and triethylamine (0.04 mL, 0.21
mmol) dissolved in MeCN was added drop-wise during a 15 min period, and the
stirred for an additional 12 hours at 0°C under dry nitrogen. Next, a solution of
dibenzyl hydroxyphosphonate 17a (77.0 mg, 0.021mmol) and triethylamine (0.04 mL,
119

Chapter 7 – Experimental

0.21 mmol) in THF was added drop-wise during 10 min to the reaction mixture, the
reaction temperature was allowed to increase to room temperature and stirring for 6
hours. The reaction progress was monitored with TLC. The solvents were evaporated,
and anhydrous t-butyl hydroperoxide in decane in THF (0.09 mL, 0.5 mmol) was
added into the residue and stirred overnight. After the reaction, THF was removed and
the residue was purified by silica gel chromatography column. Analysis by 1H NMR
spectroscopy and MS revealed the presence of by-product 61 and the starting material
tri-N/O-acetylated cytidine 18 but no expected product.
The by-product dibenzyl phosphonate (61) was obtained after
flash chromatography of the reaction product from the attempted
phosphotriester (22a) preparation. Rf = 0.48 (silica, EtOAc).
1

H NMR: (CD3Cl, 500 MHz): δ 4.99-5.08 (m, 4H, 4×CH2Ph),

6.90 (d, 1JP-H = 690.0 Hz, 1H, HPO), 7.28-7.31 (m, 10H,
10×ArH).
LRESI-MS: m/z 285 [M + Na]+.
Method B: The preparation of this compound was attempted according to
Method A with the following modifications: MeCN was chosen as solvent due to its
polarity. Benzyl alcohol was added into a solution of PCl3 under -20 °C over a 1 hour
period. Analysis by 1H NMR spectroscopy and MS revealed by-product 61 and
starting material tri-N/O-acetylated cytidine 18 again, but no expected product.
Method C: This compound was prepared according to the method reported by
Quintero et al.[100] To a solution of benzyl alcohol (0.02 mL, 0.21 mmol) and
triethylamine (0.04 mL, 0.21 mmol) in dry MeCN (5 mL) was added dropwise
phosphoryl chloride (0.02 mL, 0.21 mmol). The reaction mixture was allowed to react
for 2 hours before adding a solution of tri-N/O-acetylated cytidine 18 (80 mg, 0.021
mmol) and triethylamine (0.04 mL, 0.21 mmol) dissolved in MeCN. The reaction
mixture was stirred for 3 hours. A solution of dibenzyl hydroxyphosphonate 17a (77
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mg, 0.021 mmol) and triethylamine (0.04 mL, 0.21 mmol) was consequently added
into the mixture and the reaction mixture was stirred overnight. After reaction, MeCN
was concentrated and the residue was purified by silica gel chromatography column.
Analysis by 1H NMR spectroscopy and MS revealed starting material benzyl alcohol,
tri-N/O-acetylated cytidine 18 and dibenzyl hydroxyphosphonate 17a but no expected
product.
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7.5 Biological Assay Procedure
Protein kinase A inhibitory activity was determined according to the Kinase-Glo®
Luminescent Kinase Assay (Promega Co, Madison, WI, USA) [140] with minor
modifications as used in our laboratory. Purified PKA and specific kinase substrate
(kemptide) were purchased from Promega and used as supplied. The PKA inhibitory
activity of the extracts was determined in opaque 96 white well plates (Corning)
according to the manufacturer’s instructions.[140] All the compounds were tested at
100 μg/mL. Measurements were performed in triplicate and data are presented as
means ± S.E.M. The assay was performed in collaboration with my co-worker Ms.
Janice McCauley, who is currently performing her doctoral studies in our research
group.
1. To wells A/F1-8 of a 96-well plate, add 5 μL of the 1 mg/mL stock solution of
the test compounds, which gave a final concentration of 100 μg/mL sample in
2% DMSO. To the positive control wells (G1-6) and the negative control wells
(H1-6), add 5 μL of the 20% DMSO solution (see Table 7.1).
2. To wells G/H7-8, add 5 μL of the internal standard (staurosporine).
3. Thaw a single tube of the enzyme (250 units per tube) and make up to 2 mL
with the kinase reaction buffer to give a concentration of 125 units/mL. This
gave a final concentration of 50 units/mL (or 2.50 units/well).
4. To six of the positive control wells (G1-6), add 20 μL of the reaction mixture
containing 2.5 X the optimal concentration of kinase in kinase reaction buffer.
The positive control should provide 100% luminescence. There was 1880 μL
of this reaction mixture remaining.
5. Add 20 μL of the kemptide (PKA peptide substrate, 10 mg/mL) to the
remaining 1880 μL of kinase mixture. This provided 200 μg of the kinase
substrate in 1900 mL to give a 140 μM substrate/enzyme solution in buffer.
This amount was sufficient for 1 x 96-well plate, giving a final concentration
of 56 μM in each well per 50 μL reaction.
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6. To all remaining wells, add 20 μL of the above reaction mixture (step 5)
containing 2.5 X the optimal concentration of kinase and kinase substrate in
1X kinase reaction buffer. (Negative controls, 0% luminescence).
7. To all wells, add 25 μL of the ATP solution (20 μM, stock 3 ATP solution).
This gave a final concentration of 10 μM in each well per 50 μL reaction. See
(Table 7.1) for a summary of the reagent volumes added to the 96-well plate.
8. Using a plate shaker, gently shake the plate and incubate at room temperature
for the optimal amount of time.
9. Prepare Kinase-Glo® reagent: The kinase buffer was stored in the freezer and
thawed at room temperature. Add the Kinase-Glo® Substrate to the KinaseGlo® Buffer and add 50 μL of this mixture to each well.
10. Mix the plate and incubate for 10 minutes at room temperature, after which the
luminescence was measured using a BMG Labtech FLUOstar Optima®
luminometer (BMG Labtech Pty. Ltd., Mornington, Australia).

Table 7.1 Kinase assay plate preparation: wells A-F[1-8] are the test compounds; wells G1-6 are
positive controls; wells H1-6 are negative controls; and H7-8 and G7-8 are internal reference standards
(Std).
1

2

3

4

5

6

7

8

A

16a

16c

16d

16e

16f

16g

16h

16i

B

16a

16c

16d

16e

16f

16g

16h

16i

C

16a

16c

16d

16e

16f

16g

16h

16i

D

17a

17c

17d

17e

29

17g

17h

17i

E

17a

17c

17d

17e

29

17g

17h

17i

F

17a

17c

17d

17e

29

17g

17h

17i

G

Positive Control (100% Luminescence)

Std1a

Std1a

H

Negative Control (0% Luminescence)

Std1b

Std1b
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